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         T10c12 conjugated linoleic acid (t10c12 CLA) causes the reduction of triglyceride 
contents in adipocytes. T10c12 CLA’s delipidation effect is associated with decreased 
nutrient uptake, adipogenesis, lipogenesis, and increased energy expenditure, lipolysis, 
fatty acid oxidation in adipocytes. However, the molecular mechanisms of CLA’s 
delipidation effects are still unknown. AMP-activated protein kinase (AMPK), a central 
regulator of cellular energy levels, is activated by an increase in the cellular AMP:ATP 
ratio or various cellular stresses. We demonstrated that t10c12 CLA activated AMPK in 
3T3-L1 adipocytes, leading to inhibition of anabolic biosynthesis and increase of energy 
expenditure. Strong activation of AMPK can induce an inflammatory response, which is 
required for effective delipidation in t10c12 CLA-treated adipocytes. Sirtuin 1 (SIRT1), a 
NAD+-dependent histone/protein deacetylase that regulates energy homeostasis, is 
functionally required for robust TG reduction in response to t10c12 CLA in adipocytes. 
SIRT1 activated by t10c12 CLA is able to activate AMPK, and functions coordinately with 
AMPK to enhance TG loss. Activated SIRT1 is also capable of repressing peroxisome 
proliferator-activated receptor γ (PPARγ) activity to increase delipidation in t10c12 CLA-
treated adipocytes. However, the activation of PPARγ by its agonists, essential for 
adipogenesis and maintenance of adipocytes, strongly reduced AMPK activity and 
attenuated TG loss in t10c12 CLA-treated adipocytes. T10c12 CLA also activated PPARδ, 
 a nuclear receptor that regulates fatty acid oxidation, and PPARδ agonists and antagonists 
increased or decreased AMPK activity, respectively. Activated PPARδ competed more 
effectively for RXR, an obligate partner for many nuclear receptors, and reduced the 
amount of PPARγ/RXR protein complex present. Our studies define the 
Sirt1/AMPK/PPARγ axis as the key regulatory point for determining whether adipocytes 
increase or decrease TG levels, with activated SIRT1 and AMPK promoting TG loss and 
PPARγ opposing this loss.   
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Chapter I. Review of Literature 
 
Conjugated linoleic acid and delipidation 
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Introduction 
 
         Obesity has become a global epidemic disease, with more than 1 billion adults overweight 
and more than 300 million of them clinically obese. Recently, at least 155 million children 
worldwide are overweight or obese, causing concerns about the increasing incidence of child 
obesity [1]. Even in many developing countries, the rising rate of overweight and obesity is a 
growing concern, with a faster increase than in the developed world [2]. Obesity is associated 
with many diseases, particularly heart disease, type 2 diabetes, breathing difficulties during sleep, 
certain types of cancer, and osteoarthritis [1,2]. Currently, obesity and type 2 diabetes are the 
leading metabolic diseases. There is a great need for the prevention and therapeutic strategies 
against these health diseases. For the obesity therapeutics, many current strategies are based on 
inhibiting satiety and doing exercise, but none of the current treatments are effective for 
controlling body weight or reducing obesity.  
             It has been clearly demonstrated that conjugated linoleic acid (CLA) is able to 
significantly reduce body fat, particularly abdominal fat, decrease the level of serum lipids, 
decrease glucose uptake, and increase lipid oxidation [3]. CLA [18:2(n-6)] refers to a family of 
polyunsaturated fatty acids (PUFAs) that exist as conjugated stereoisomers of linoleic acids [4]. 
Early in 1979, Pariza et al. found that tumorigenesis in a mouse model was inhibited by certain 
components from grilled beef [5]. In 1987, they identified CLA as the active component to 
provide beneficial effects [6]. CLA has at least 13 isomers, which are found primarily in the meat 
and dairy products of ruminants [4]. CLA can be synthesized by anaerobic bacteria through 
biohydrogenation in the ruminant animals [7].  CLA has very broad beneficial effects such as 
anticarcinogenic, antioxidant, antiatherosclerosis, antiatherogenic, and antidiabetogenic 
properties [8-10]. The promising application of CLA as a therapeutic strategy to these diseases 
   
3
has received great attention. Whereas, some differences appear in CLA effects between species 
[11]. Two main CLA isomers, c9t11 and t10c12, have some different biological effects. 
Compared to the c9t11 isomer, t10c12 CLA has much stronger delipidation effects both in vitro 
and in vivo [12-15]. 
CLA induces delipidation  
            As early as 1997, the delipidation effect of CLA was reported by Park et al. Consumption 
of feed including 0.5% mixed CLA for 4-5 weeks (1:1 ratio of c9t11 and t10c12)  in ICR 
(Institute for Cancer Research) male and female mice decreased body fat mass by 60% [16]. In 
this study, the delipidation mechanism proposed that t10c12 CLA increased lipolysis and fatty 
acid oxidation, but reduced fatty acid uptake in adipocytes. In another study of atherogenic diet-
fed hamsters, diet containing 0.5% t10c12 CLA for 6 weeks caused a significant reduction of fat 
mass [17]. For Zucker diabetic fatty rats, 1.5% mixed CLA was able to decrease fat mass 
significantly [10]. For the delipidation effect of CLA, most of the experiments showed that 
t10c12 isomer, not the c9t11 isomer, plays the primary role in the reduction of fat mass. The data 
from our lab demonstrated that mice fed 0.5% t10c12 CLA for 2 weeks lost more than 75% of 
white adipose tissue (WAT) mass in the retroperitoneal (RP) and epididymal (EPi) fat tissues 
[12]. Interestingly, more fat loss is induced by CLA in RP than EPi. This suggests that the 
response sensitivity to CLA is dependent on the type of fat tissue. T10c12 CLA was also 
reported to induce significant delipidation in other animals, including chickens [18], rabbits [19] 
and porcine [20]. Interestingly, when eliminating CLA from the diet, the accumulation of TG is 
recovered in the fat tissues. This suggests that the fat loss is reversible when CLA is removed, 
indicating CLA doesn’t destroy adipocytes. 
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             CLA’s delipidation effect on animals is associated with exercise. It has been recently 
reported that high-fat diet-fed BALB/C male mice treated with the mixture of 0.4% CLA (50:50 
c9t11+t10c12) and moderate treadmill exercise for 14 weeks showed reduced body fat mass, 
decreased serum leptin levels, as well as increased oxygen consumption and energy expenditure 
[21].  
              In vitro, the delipidation effect was shown in the CLA-treated 3T3-L1 cell line and 
human primary cells. Park et al. reported that 20-200 µM of t10c12 CLA was able to cause the 
decrease of TG content in 3T3-L1 adipocytes [22]. Studies in our lab also showed 100 µM of 
t10c12 CLA caused the robust loss of TG content by 50% in the mature 3T3-L1 adipocytes, as 
compared to control treatment [23]. McIntosh group showed that 3-30 µM t10c12 CLA was able 
to inhibit the preadipocyte differentiation and decrease TG content in primary human stromal 
vascular (SV) cultures [24]. Although the robust delipidation effect of t10c12 CLA was reported, 
the isomer-specific delipidation mechanism of CLA is still not clearly known. 
           T10c12 CLA has been demonstrated to induce dramatic fat loss in human SV adipocyte 
cultures [24]. However, most of the human studies have not shown the significant delipidation 
effect observed in animal and cell line studies. There are few positive delipidation effects of 
t10c12 CLA reported in some short- and long-term studies in human trials, showing the 
beneficial effects of t10c12 CLA in reducing fat mass [25-27]. The reason for the limited 
delipidation effects of t10c12 CLA in human trials may be because t10c12 CLA dosage used in 
human studies is much lower than used in animal studies [28]. In these human studies, a dosage 
of 3.4 g per day has been used , while the dosage used in mice is at least 10 times this amount per 
kg bodyweight [29]. To increase effective delipidation in humans, our goal is to combine t10c12 
CLA with other nutritional supplements to attain the synergistic effects to induce respectable fat 
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loss at a lower CLA dose than used in mice. This has great potential for inducing adiposity in 
human trials. 
Adipocyte 
 
           Adipocytes are the main target of the CLA delipidation effect. The majority of dietary 
CLA enters into adipocytes. Improving our understanding of adipocyte biology is the key to 
determining the mechanism of CLA’s delipidation effects. Mesenchymal stem cells (MSC) can 
generate a common early preadipocyte, which can be further differentiated to committed white 
adipocyte under certain stimuli. The number of preadipocytes in adipose tissue is limited [30]. 
During adulthood, the number of fat cells remains consistent in lean and obese humans, even 
after marked weight loss. About 10% of adipocytes renew every year [31]. 
           Peroxisome proliferator activated receptor-γ (PPARγ) and CCAAT/Enhancer Binding 
Protein α (C/EBPα) are two important transcriptional factors in the differentiation of 
preadipocytes to adipocytes. As the master regulator of adipogenesis, PPARγ is both necessary 
and sufficient to enable the preadipocytes to differentiate into adipocytes [32]. PPARγ is a 
nuclear hormone receptor and has two different isoforms produced by alternative splicing of the 
PPARγ mRNA. PPARγ1 is ubiquitously expressed, but PPARγ2 is mainly expressed in adipose 
tissue [33]. Some synthetic PPARγ ligands, such as thiazolidinediones (TZDs), can activate 
PPARγ. PPARγ forms a heterodimer with retinoid acid receptor (RXR). The heterodimer is able 
to activate the transcription of adipogenic target genes by binding to peroxisome proliferator 
response elements (PPREs) in their promoters [34]. Adipocyte differentiation was promoted by 
overexpression of PPARγ2 in fibroblasts [35]. In contrast, adipocytes can not be formed without 
PPARγ2 [36]. In a conditional knockout to create a PPAR γ2-deficient mouse model, the 
amounts of adipose tissue were decreased compared to wild type mice [37]. 
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         C/EBPα is a transcription factor that also plays an important role in adipogenesis by 
interacting with PPARγ. C/EBPα can activate the transcription of adipogenesis genes such as 
PPARγ and aP2 by binding to their promoters [33]. C/EBPα is sufficient to enhance preadipocyte 
differentiation. In 3T3-L1 preadipocytes, C/EBPα knockdown prevents adipocyte differentiation 
[38]. In vivo, with C/EBPα-deficient mice, the number of adipocytes was reduced in the adipose 
tissue, compared to wild-type mice [36]. 
          Interestingly, PPARγ and C/EBPα promote adipogenesis in a coordinated manner: PPARγ 
and C/EBPα positively increase the expression each other. Whereas in the absence of C/EBPα, 
reduced levels of PPARγ still can stimulate adipogenic differentiation but weakly. However, 
reduced levels of C/EBPα can’t induce adipogenesis in the absence of PPARγ [36]. This suggests 
that PPARγ is essential in the differentiation of adipocytes. 
          Preadipocyte factor-1 (Pref-1) is a transmembrane protein containing epidermal growth 
factor-like domains. Pref-1 has very high expression in 3T3-L1 preadipocytes, while it is highly 
suppressed during adipocyte differentiation, becoming undetectable in mature adipocytes. Pref-1 
prevents adipogenesis by inhibiting PPARγ and C/EBPα expression [39]. Suppression of Pref-1 
is required for adipocyte differentiation. In 3T3-L1 preadipocytes, decreasing Pref-1 levels by 
siRNA knockdown promotes adipogenesis [40]. In vivo, in Pref-1 deficient mice, the body 
weight and fat depots were increased more rapidly, compared to wild-type mice [39]. 
Conditional transgenic mice overexpressing Pref-1 in adipose tissue, using the aP2 promoter, 
showed decreased adipose tissue mass, compared to wild-type mice [41, 42]. This indicates that 
overexpression of a preadipocyte specific gene in differentiating adipocytes can inhibit further 
differentiation. 
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         There are two types of adipose tissue in mammals. White adipose tissue (WAT) stores 
energy as triglycerides. When energy shortage such as fasting happens, release of fatty acids 
from triglyceride in white adipocyte into the plasma by lipolysis is used to supply the energy to 
the body. Although brown adipose tissue (BAT) shares many features with white adipocytes, 
BAT plays a physiological function in fatty acid oxidation and thermogenesis, which is opposite 
to that of white adipocyte. The brown adipocyte contains lots of smaller droplets and numerous 
mitochondria which contain iron which make the tissue brown. In contrast, the white adipocyte 
contains a single and large lipid droplet and fewer mitochondria [43]. 
          White adipose tissue has a low intrinsic oxidative capacity. Current research showed that 
the limited fatty acid oxidation in white adipocytes comes from the low protein level of 
uncoupling protein 1 (UCP1), peroxisome proliferator-activated receptor coactivator-1α and fatty 
acid re-esterification involved enzymes [44]. The expression of uncoupling protein 1 (UCP1) in 
numerous mitochondria is essential for fatty acid oxidation and heat generation in brown 
adipocytes. UCP1 uncouples ATP synthesis and oxygen consumption to enhance energy 
dissipation as heat. The detailed mechanism is that UCP1 diverts energy from ATP synthesis to 
thermogenesis in the mitochondria by leaking protons out of the mitochondria [45]. Transgenic 
C57BL6/J mice expressing UCP1 from the adipocyte lipid-binding protein (aP2) promoter are 
capable of reducing genetic and diet-induced obesity [46]. However, in human intraperitoneal 
adipose tissue, it was estimated that 0.5-1% of adipocytes express UCP1 [47, 48]. Interestingly, 
the microarray data in our studies showed that UCP1 mRNA levels dramatically increased by 26 
fold in RP tissues, as compared to the control group, when the mice were fed 0.5% CLA for 2 
weeks [12].  
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The mechanism of t10c12 CLA-induced delipidation 
T10c12 CLA causes little change in feed intake 
           Generally, food intake is a starting point to study t10c12 CLA’s delipidation effect. Most 
studies, including our recent studies [12], in mice, rats and pigs showed that t10c12 CLA has no 
effect on feed intake. However, a few studies showed that t10c12 CLA caused a little loss of 
appetite in animals [49]. Further studies indicated a slight reduction in feed intake does not 
completely account for a significant reduction in fat mass [50]. 
T10c12 CLA inhibits adipogenesis 
          Adipogenesis is a differentiation process in which preadipocytes become adipocytes. 
T10c12 CLA can inhibit differentiation in a dose-dependent manner via the inhibition of  the key 
transcription factors of adipogenesis, including PPARγ, C/EBPα, PPARγ co-activators and fatty 
acid binding proteins [23]. Our studies based on 3T3-L1 cells and mouse models also showed 
t10c12 CLA can decrease the protein level of adipogenesis associated genes, and increase the 
expression of preadipocyte factor-1 (Pref-1) , which is an inhibitor of adipogenesis [12].  
T10c12 CLA inhibits lipogenesis 
 
          Lipogenesis is a process by which fatty acids are synthesized and esterified to glycerol. 
Sterol regulatory element-binding proteins (SREBPs) are one class of important transcription 
factors to regulate the process of lipogenesis. SREBPs function by binding to the sterol 
regulatory element DNA sequence. Inactive SREBPs attach to the membranes of the nuclear 
envelope and endoplasmic reticulum. Low sterol levels is enough to trigger the cleavage of 
SREBPs to a water soluble N-terminal domain, which is able to translocate into the nucleus and 
enhance the sterol synthesis. The cleavage of SREBPs is then inhibited by increased sterol level 
through a negative feedback regulation. SREBP-1c is responsible for regulation of fatty acid 
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synthesis [51]. It was reported that t10c12 CLA’s delipidation effect was associated with the 
inhibition of SREBPs [23]. T10c12 CLA may down-regulate SREBP-1c and LXR-α, then inhibit 
the transcription of genes involved in fatty acid synthesis and fatty acid elongation, including 
acetyl CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD), 
glycerol phosphate acyltransferase and acylglycerol phosphate acyltransferase [12]. Other down-
regulated pathways involved in sterol biosynthesis are associated with leucine degradation, 
ubiquinone biosynthesis, and amino acid metabolism. Our microarray data also showed that the 
mRNA levels of lipid biosynthetic genes decrease, including ATP citrate lyase and acetyl Co-A 
carboxylase alpha and beta, in t10c12 CLA-treated 3T3-L1 adipocytes and WAT [12]. Other 
genes involved in the inhibition of lipogenesis include acylation-stimulating protein, caveolin I, 
and lipin 1, which had decreased mRNA level in t10c12 CLA treatment. 
T10c12 CLA increases energy expenditure 
         T10c12 CLA was reported to increase energy expenditure [52]. As a mitochondrial enzyme, 
carnitine palmitoyltransferase 1 (CPT1) is a rate-limiting enzyme for fatty acid beta-oxidation. 
CPT1 helps transport fatty acids across the membrane via carnitine, and enhance fatty acid beta-
oxidation in the mitochondria. This enzyme can be inhibited by malonyl CoA, which is produced 
by acetyl-CoA carboxylase (ACC). ACC is able to convert acetyl-CoA to malonyl-CoA and 
supply the malonyl-CoA substrate for fatty acid synthesis. Therefore, the reduction of malonyl-
CoA increases the activity of CPT-1, increases the transport of fatty acids into mitochondria, and 
consequently, increases fatty acid oxidation rate [53]. The work from Park et al. showed that 
t10c12 CLA increased the activity of CPT1 in mitochondria [22]. In their further studies, they 
concluded that fatty acid oxidation is an important factor to decrease body fat in the treatment of 
t10c12 CLA. It was also reported that CPT1 mRNA increased in t10c12 CLA-fed mice [12]. 
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Other studies showed most of the energy expenditure was derived from increased metabolic heat 
output in t10c12 CLA-fed mice [52]. Our recent studies also demonstrated that transcriptional 
levels of key genes involved in fatty acid oxidation such as UCP1, UCP2 and CPT1 increased in 
the fat tissues when the mice were fed with the diet contained 0.5% CLA for 2 weeks [12]. The 
levels of the induced mRNAs of UCP1 and UCP2 genes are very abundant, accounting for 95% 
and 90% of the most abundant mRNAs in WAT, respectively [12]. 
T10c12 CLA increases lipolysis 
            The form of energy stored in white adipose tissue is triglyceride. Lipolysis is the 
breakdown of triglycerides into free fatty acids, which are then released into the blood. Lipolysis 
is a main means to export energy with free fatty acids and glycerols from adipocytes [54]. 
Perilipin proteins coat oil droplets in adipocytes, acting as a protective coating from breakdown 
by lipases into glycerol and free fatty acids [55]. Perilipin A is most abundant in mature 
adipocytes. Adipocyte differentiation-related protein (ADRP) is a major constituent of the 
globule surface of oil droplets in adipocytes [56]. Compared to perilipin, ADRP has high mRNA 
level in the early stage of adipocyte differentiation, but low at the large lipid droplet stage in 
mature adipocytes. This suggests ADRP inhibits the formation of oil droplets and tends to 
decrease TG accumulation in adipocytes. Chung et al. reported that t10c12 CLA increased 
lipolysis in human SV adipocyte cultures [57]. The mechanism was t10c12 CLA increased 
ADRP protein expression, which eliminates the perilipin A proteins. The decreased perilipin A 
protein coating enhanced fat acid release via lipolysis. Further studies indicated that 
phosphorylation of perilipin (active form) was regulated by the cAMP-PKA axis in t10c12 CLA 
treatment. The recent microarray data from our lab supported the increased lipolysis in CLA 
treated mice [12]. The highly expressed genes involved in lipolysis include monoglyceride lipase, 
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hormone sensitive lipase and lipase A. Interestingly, the products glycerol and FFA from 
lipolysis can be re-utilized to synthesize TG, and ATP consumption is required [58]. In this 
process, called a futile cycle, the increased lipolysis enhances energy expenditure. In this case, 
t10c12 CLA might utilize a novel mechanism to increase energy expenditure, which is beneficial 
for obesity and diabetes therapeutics. 
T10c12 CLA inhibits nutrient uptake 
         Glucose and fatty acids are two major sources for triglycerol synthesis in adipocytes. 
Brown et al. reported t10c12 CLA inhibited the uptake of glucose into primary human 
adipocytes by decreasing glucose transporter 4 (GLUT4) gene expression [59]. In this study, 
t10c12 CLA also inhibited the uptake of oleic acids. In the study of 3T3-L1 adipocytes and 
mouse models, including our recent studies, t10c12 CLA significantly reduced the activity of 
lipoprotein lipase (LPL), which is an enzyme involved in the uptake of fatty acids by adipocytes 
[12]. The inhibition of glucose and fatty acid uptake resulted in the reduction of synthesis of 
triglycerides. In our studies, another gene involved in the inhibition of glucose and fatty acid 
uptake is the facilitated glucose/fructose transporter member SLC2A5, which had decreased 
mRNA levels in the t10c12 CLA treatment.  
T10c12 CLA induces inflammation response 
          Inflammation response is induced in the t10c12 CLA-treated adipocyte cultures and WAT 
[12]. The studies from the McIntosh group showed that t10c12 CLA imparted its effects to 
activate ERK1/2 and NFκB [60]. NFκB p65/p50 was activated by phosphorylation of ERK when 
the NFκB subunit complex translocated to the nucleus of SV cells. Activated NFκB enhanced the 
expression of some cytokines like TNF-α, IL-6 and IL-8. Subsequently, these secreted cytokines 
bind to their receptors on the adipocyte surface, leading to enhanced inflammation response in a 
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positive feedback. As a consequence, the inflammation response results in the suppression of 
PPARγ, C/EBPα, aP2, sterol-CoA desaturase (SCD), LPL, FAS, Glut4 and PLIN. The 
inflammation response causes a reduction in glucose and fatty acid uptake, and inhibition of 
Adipogenesis and lipogenesis, but increase of lipolysis, consequently contributing to delipidation 
in adipocytes. Histologically, our recent studies in mouse model showed the density of 
macrophages was increased in t10c12 CLA-treated RP fat tissue, about 2 times as many as in the 
control [12]. The microarray data showed that the first several days of dietary CLA induced an 
inflammatory response, including IL-1, 6, 10, 15 and 17, their receptors and CXC or CC ligand 
family members [12]. Interestingly, this initial inflammatory response was transient and the 
expression levels of many of these genes returned to normal levels after the first week of CLA 
treatment. Most of these genes express less at later times than in the initial response. Some 
pathways involved in the CLA-induced inflammation response include Jak/Stat, ERK/MAPK, 
PI3K/AKT signaling.  
T10c12 CLA induces apoptosis  
          Apoptosis is a form of programmed cell death (PCD) in multicellular organisms. T10c12 
CLA was reported to reduce adipose tissue mass by initiating apoptosis [12]. This study showed 
that CLA induced apoptosis through p53-dependent and/or independent pathways, depending on 
the cell type [61]. In an in vitro study in the estrogen-unresponsive MDA-MB-231 breast cell 
line, CLA triggered apoptosis through the reduction of the anti-apoptotic protein Bcl-x and up-
regulation of the pro-apoptotic protein Bak [62, 63]. Further studies showed that t10c12 CLA 
induced caspase-dependent apoptosis, due to decreased bcl-2 and increased p21 (WAF/Cip1) 
expression [64]. This suggests that t10c12 CLA mediates its effects partially via the modulation 
of apoptosis and cell cycle control [65]. Previous studies in our lab using a polygenic obese line 
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of mice (M16) by Miner et al. also showed that apoptosis in MI-CLA fed mouse retroperitoneal 
fat pads was 4 fold higher than the control mice [66]. Our recent studies in the mouse model 
showed the number of adipocytes in fat tissues was reduced by 15% [12]. Interestingly, 
adipocyte cell size became smaller, with about a 90% reduction in cell volume. Our microarray 
analysis in CLA-treated 3T3-L1 adipocytes and WAT demonstrated the induction of numerous 
genes involved in apoptotic signaling, including a number of death receptors and their ligands, 
TNF ligands, and TNF responsive genes, MdM-2, APAF1, BAX, PMAIP1, MCL1 and DNA 
repair involved such as PCNA and GADD45B, and cell cycle arrest-associated gene CDKNA1 
(pRB), proinflammatory initiator caspases 1 and 4 [12]. 
T10c12 CLA induces integrated stress response 
        The inflammation response and apoptosis contribute to t10c12 CLA-induced delipidation. 
In our recent studies, integrated stress response (ISR) appears early and is able to trigger an 
inflammation response and apoptosis [67]. Integrated stress response (ISR) is triggered by 
phosphorylation of eukaryotic initiation factor 2α (eIF2 α) under certain stress stimuli such as 
endoplasmic reticulum (ER) stress in response to an accumulation of unfolded or misfolded 
proteins in the lumen of ER. We found ISR to be the earliest transcriptional response to t10c12 
CLA treatment in 3T3-L1 adipocytes or in WAT in mice [12]. The ISR might be a key 
regulatory point in the delipidation response to CLA. By examining gene expression between 4 
and 24 hrs after t10c12 CLA treatment for both mice and 3T3-L1 adipocyte cell line, our study 
suggested that the release of proinflammatory cytokines by ISR played an important role in the 
induction of the later inflammatory response. The release of proinflammatory cytokines may 
explain how ISR causes lipid loss in mature adipocytes. We further studied the potential t10c12 
CLA effect-mediated pathways associated with the increase of phosphorylation of eIF2, which 
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reduces the rate of protein translation initiation. Phosphorylation of eIF2 induces ATF4, 
activating ISR/UPR genes including ATF3, CHOP and TRB3, which are involved in cell stress 
survival and apoptosis, and NFκB, which initiates an inflammatory response. ISR can induce the 
dephosphorylation of GSK3β by excluding AKT2 from nucleus, and subsequently causes the 
inhibition of SREBP1c [68].  
Conclusion 
         T10c12 CLA is able to cause dramatic delipidation in cell culture and animal models. The 
mechanism is associated with inhibited nutrient uptake, Adipogenesis and lipogenesis, but 
increased energy expenditure, lipolysis, fatty acid oxidation, inflammation, apoptosis and ISR. 
Despite numerous studies to describe the responses to t10c12 CLA, its molecular mechanism are 
still unknown. My thesis attempted to discover additional mechanisms by which delipidation is 
induced by t10c12 CLA at the molecular level. We were particularly interested in the early 
events in an effort to eventually discover the mechanism initially responding to the presence of 
CLA. My results explain much of the mechanisms leading to the delipidation response to CLA. 
The initial “receptors” are waiting for further investigation .  
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Introduction 
           Conjugated linoleic acid (CLA) isomers of linoleic acid (LA) are found in dairy products 
and cause reduced adiposity in mice [69]. The trans-10, cis-12 CLA (t10c12 CLA) isomer of 
CLA causes rapid fat loss when fed to mice or in human adipocytes cultured in its presence [16, 
60, 69]. T10c12 CLA increases fatty acid oxidation [70], apoptosis [71], lipid export [57] and an 
inflammatory response [72] in differentiating or mature adipocytes.  It also reduces glucose and 
fatty acid uptake [73] as well as reducing lipogenesis [71, 73, 74]. These cumulative 
physiological changes account for the fairly rapid and dramatic loss of lipids in t10c12 CLA-
treated adipocytes [24, 75].  
The molecular responses accompanying these physiological changes are remarkably 
diverse [24] and include the integrated stress response [ISR; [67]] or the unfolded protein 
response [UPR; [76]], a nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
mediated inflammatory response [60], and mitogen-activated protein kinase (MAPK) cascades 
[57].  The ISR induces activating transcription factor 3 (ATF3) and activating transcription factor 
4 (ATF4) proteins as well as possibly activating NF-κB and an inflammatory response [60, 67]. 
The occurrence of the UPR, which includes the ISR and inflammation, is an emerging theme in 
chronic metabolic diseases such as type 2 diabetes [77, 78]. The ability of t10c12 CLA to 
selectively activate only the ISR component of the UPR [67] may account for its ability to cause 
selective reduction of the white adipose tissue (WAT) mass [79]. The transcripts and/or protein 
activities of key adipocyte transcription factors such as CCAAT enhancer binding protein α 
(C/EBPα), peroxisome proliferator-activated receptor γ (PPARγ), sterol regulated element 
binding protein 1c (SREBP1c), carbohydrate-response-element-binding protein (ChREBP), and 
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important lipogenic enzymes including acetyl-CoA carboxylase (ACC) and fatty acid synthase 
(FAS) are reduced when adipocytes are exposed to t10c12 CLA [12, 24, 50, 67].   
AMP-activated protein kinase (AMPK) is a central regulator of cellular energy levels.  
Increases in the cellular AMP/ATP ratio or various cellular stresses result in the activation of 
AMPK [80, 81].  AMPK is a heterotrimeric protein and the activity of the AMPKα catalytic 
subunit is controlled by the AMPKβ and AMPKγ regulatory subunits as well as phosphorylation 
at a conserved threonine (Thr-172).  AMPK substrates include a number of biosynthetic enzymes 
such as ACC, FAS, glycerol-3-phosphate acyltransferase (GPAT), and 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR).  Phosphorylation of these proteins reduces their activity 
and leads to decreased energy consumption in their respective biosynthetic pathways as well as 
increased fatty acid oxidation to increase energy production [80, 82].  The activity of AMPK can 
be modulated by several known chemical inhibitors and activators.  Compound C is a potent 
inhibitor of AMPK while drugs such as 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR), metformin, and thiazolidinediones activate AMPK [80].    
In the present study, we analyzed the participation of AMPK in the t10c12 CLA-
mediated lowering of triglycerides (TG) in 3T3-L1 adipocytes.  Our objectives were to determine 
whether t10c12 CLA activated AMPK, AMPK activators or an inhibitor affected the 
biochemical and transcriptional responses, an inflammatory response was required, and whether 
metformin enhanced the reduction in adiposity in mice given a low dose of t10c12 CLA.   
Methods 
Reagents. Insulin, isobutyl-1-methylxanthine, dexamethasone, bovine serum albumin (BSA, > 
99% fat free), AICAR and metformin were from Sigma (St. Louis, MO). Bay11-7082 and 
AMPK inhibitor compound C were purchased from Calbiochem (San Diego, CA). Antibodies to 
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ATF3, ATF4, NF-κB p65, Lamin B, PPARγ, SREBP-1c, and C/EBPα were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA), while those to p-AMPK, AMPK, p-ACC, and ACC 
were from Cell Signaling (Beverly, MA).  The antibodies to p-ACC and ACC recognize both 
ACC1 and ACC2.  
Animals. Forty-two metabolism-low (ML) and forty-two metabolism-control [MC; [83] ] 12-wk 
old male mice were used. Mice were housed individually at 22 °C with 12 h light and 12 h dark. 
All mice were fed AIN-93G diet ([84]; Dyets, Inc., Bethlehem, PA) for 5 d before beginning the 
treatments. Mice were blocked by initial body weight (ML 33.8 ±  2.2 g; MC 35.7 ±  1.9 g; 
within genotype) and assigned to one of the seven treatment diets.  Specific diets contained either 
70 g/kg soy oil without t10c12 CLA or 67.5 g/kg soy oil with 2.5 g/kg t10c12 CLA. Mice were 
allowed to eat ad libitum. Metformin, when present, was dissolved in distilled drinking water to 
provide 2 or 20 mmol/L, and these solutions were changed every 3 days.  After 14 d of these 
treatments, mice were killed in the fed state between 09:00 and 13:00 h by carbon dioxide 
asphyxia.  Retroperitoneal and epididymal fat pads were harvested, weighed, flash frozen in 
liquid nitrogen, and stored at −80 °C. All procedures were approved by the University of 
Nebraska Institutional Animal Care and Use Committee. 
3T3-L1 cell culture and differentiation. 3T3-L1 fibroblasts [85] were cultured in Dulbecco's 
modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) containing 10% bovine calf serum 
(Fisher, Pittsburgh, PA) and differentiated as described [86]. In brief, two days after growing to 
confluence, the cells were induced to differentiate by DMEM containing 10% fetal bovine serum 
(FBS; Fisher, Pittsburgh, PA), 0.17 µmol/L insulin, 0.5 mmol/L isobutyl-1-methylxanthine, and 
1 µmol/L dexamethasone for 3 days. The medium was then changed to 10% FBS/DMEM with 
0.17 µmol/L insulin for another 2 days, at which time the cells were usually differentiated to at 
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least 90% adipocytes, followed by basal 10% FBS/DMEM medium before initiating fatty acid 
treatments. All media contained 100,000 U/L penicillin and 172 µmol/L streptomycin 
(Invitrogen, Carlsbad, CA). When present, Bay11-7082 was used at 2 µmol/L and compound C 
was used at 10 µmol/L, and were added 1 h before adding fatty acids.  
Fatty acid treatments. Fatty acids (>99%, Nu-chek Prep, Elysian, MN), either linoleic acid or 
trans-10, cis-12 CLA, were complexed to fatty acid free BSA (>99%) in a 1:1 ratio (2 mmol/L 
BSA: 2 mmol/L fatty acid), pH adjusted to 7.4, and added to the cultures containing 5 d post-
differentiated 3T3-L1 adipocytes.  
Western blots. Nuclear and cytosolic extracts were isolated based on the manufacturer's 
protocol (Active Motif, Carlsbad, CA). Equal amounts of proteins were separated by SDS-PAGE, 
transferred to Immun-blot PVDF membrane (Bio-Rad Laboratories, Hercules, CA) and probed 
with the indicated antibodies. Enhanced chemiluminescence (Pierce, Rockford, IL) was used for 
detection. Band intensities were determined from digital images from exposures in the linear 
range using software (Quantity One, Biorad, Hercules, CA). All western blot analyses were 
repeated at least three times. 
Quantification of TG content. Cells were collected in phosphate buffer saline, aggregates 
dispersed by pipetting several times, and aliquots were used to obtain cell counts using a 
hemacytometer (Hausser Scientific, Horsham, PA), and used to calculate the original density of 
the cells. Preparation of extracts and TG measurements were performed according to the 
manufacturer using TG reagent (T2449; Sigma, St. Louis, MO) and free glycerol reagent (F6428; 
Sigma, St. Louis, MO). TG data are expressed as nmol of TG per 106 cells.  
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Measurement of MCP-1 mRNA. Total RNA was extracted by TRIzol (Invitrogen) following 
the manufacturer’s protocol. Total RNA (2 µg) was used for cDNA synthesis. Real-time PCR 
was performed by a Bio-Rad iCycler using iQ SYBR Green Supermix reagent (Bio-Rad, 
Hercules, CA). The primer sequences for MCP-1 and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were taken from [87]. MCP-1 mRNA expression was normalized to 
GAPDH, which showed no significant variation in microarrays between linoleic acid and t10c12 
CLA treatments. Experiments were repeated three times, and each sample was analyzed using 
one RNA control and two replicates of each cDNA pool, and the relative amounts of MCP-1 and 
GAPDH were calculated using the comparative CT method [according to the manufacturer’s 
software (Bio-Rad, Hercules, CA) and [88]]. Cycle numbers were used to calculate gene 
expression levels in the linear amplification range, and qRT-PCR efficiency was close to 100%. 
Microarray data analysis. RNA isolation and labeling of the 3T3-L1 adipocytes was done 
according to [12]. Results of the four treatments (linoleic acid, t10c12 CLA, linoleic acid + 2 
mmol/L metformin, t10c12 CLA + 2 mmol/L metformin) of each three biological replicates were 
collected from Affymetrix® GeneChip Mouse Genome 430 2.0 arrays via the Affymetrix 
GeneChip Operating Software (GCOS; Affymetrix, Santa Clara, CA). The raw data for 
microarray results were normalized using the methods described by Wu et al [89]. To identify 
differentially expressed genes between the control (linoleic acid) and other treatments, the linear 
models for microarrays [Limma; [90]] package in R/Bioconductor were used, with Benjamini-
Hochberg [91] adjusted P-values. Those genes with an absolute log2 ratio of 2 or more (four-fold 
up- or down-regulated) and an adjusted P-value ≤  0.1 were deemed to be significant and taken 
for further analysis. Calculation of correlation coefficients used a Spearman correlation (two-
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tailed test, α = 0.05). The gene expression data were deposited at the NCBI Gene Expression 
Omnibus with series number GSE14888.  
Statistical Analysis. Two-way ANOVA was used to analyze the data as follows. For Figures 1A, 
and 2A-E, the main effects of CLA (LA or CLA) and Compound C (- or +), and their interaction 
(CLA x Compound C) were analyzed. For Figures 1B, and 1C, the main effects of CLA (LA or 
CLA) and time (0.5, 1, 8, and 12 h), and their interaction (CLA x time) were determined. For 
Figures 3A-C, the main effects of CLA (LA or CLA) and Bay11-7082 (Bay11, - or +), and their 
interaction (CLA x Bay11) were determined. For Figures 4A-C, the main effects of CLA (LA or 
CLA) and AICAR (- or +) or Met (- or +), and their interaction (CLA x AICAR or Met) were 
determined. Data were analyzed as a 2 x 2 x 3 factorial ANOVA in the ML and MC mouse 
experiment. The model included the main effects of mouse line, CLA, and metformin, all two-
way interactions, and the three-way interaction, and used α = 0.1. Initial body weight was 
included as a covariate. Pairwise comparisons were calculated using Tukey’s test (criterion for 
significance, α ≤ 0.05, unless otherwise noted). All analyses were performed using SAS software 
(SAS, Cary, NC). 
Results 
3T3-L1 adipocytes treated with compound C, or t10c12 CLA and compound C, had TG levels 
similar to samples treated with the control linoleic acid (LA). Adipocytes treated with t10c12 
CLA alone produced a 50% reduction in TG levels (Fig. 1A). This result suggested active 
AMPK was involved in the response to t10c12 CLA.  This suggestion was confirmed as t10c12 
CLA-treated adipocytes had increased levels of both phosphorylated AMPK and phosphorylated 
ACC as early as 30 min after exposure and this enhanced phosphorylation level increased during 
the 12 h duration of the experiment (Fig. 1B and 1C).  The total amounts of AMPK and ACC 
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remained constant during the experiment (Fig. 1B and 1C), and the amounts of the isoforms of 
ACC were expected to be similar to their relative mRNA abundance in 3T3-L1 adipocytes, 
which was 4:1 for ACC1:ACC2 in a microarray analysis (data not shown). 
Compound C attenuated the ability of t10c12 CLA  to increase the phosphorylation of 
AMPK and ACC (Fig. 2A), to increase in the ISR-induced transcription factors ATF4 and ATF3, 
after 2 or 8 h of treatment, respectively (Fig. 2B and 2C), and to increase the amount of NF-κB in 
the nucleus (Fig. 2C). Compound C also attenuated the ability of t10c12 CLA to reduce the 
amounts of the key adipogenic transcription factors C/EBPα, SREBP1c, and PPARγ (Fig. 2D) 
and to increase the transcript levels of monocyte chemotactic protein-1 (MCP-1; Fig. 2E).    
NF-κB inhibitor Bay 11-7082 attenuated the t10c12 CLA-mediated reduction in 3T3-L1 
adipocyte TG levels (Fig. 3A), and inhibited the increased nuclear localization of the p65 subunit 
of NF-κB (Fig. 3B).  Bay 11-7082 also reduced the amount of MCP-1 mRNA produced in the 
presence of t10c12 CLA (Fig. 3C).   
3T3-L1 adipocytes treated with t10c12 CLA, metformin, or AICAR showed TG 
reductions of 14 to 20% when compared to the control LA treatments (Table 1). Adipocytes 
treated with a combination of either metformin or AICAR and t10c12 CLA had reductions in TG 
levels of almost 50% (Table 1). 
3T3-L1 adipocytes treated with metformin, AICAR, or t10c12 CLA, alone or in 
combination, had increased phosphorylation of AMPK and ACC after 2 or 8 h (Fig. 4 and Table 
1). The combination of t10c12 CLA with metformin produced significantly higher levels of 
phosphorylated AMPK at each time. The combination of metformin or AICAR and t10c12 CLA 
reduced the levels of MCP-1 mRNA relative to t10c12 CLA alone (Table 1).  Neither metformin 
nor AICAR alone produced a significant induction of MCP-1 mRNA.   
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The transcriptional responses to t10c12 CLA, metformin, or the combination treatment 
were further analyzed using microarrays. The hypothesis was that if similar pathways were being 
activated by the two treatments the microarray results should show a high degree of similarity. 
The gene expression changes for 3T3-L1 adipocytes treated with either metformin or t10c12 
CLA or the combination of the two produced very similar responses (Table 2 and Supplemental 
Tables 1-6). The correlation coefficients for genes with significant changes in transcript levels 
were 0.75 or better for pairwise analysis of these treatments (Table 2).  We also compared the 
expression changes for these treatments using specific lists of genes in the ISR (Supplemental 
Table 4) and lipogenesis (Supplemental Table 5) pathways that were  determined in prior 
experiments with t10c12 CLA or the UPR-inducing chemical tunicamycin [67].  The correlation 
coefficients for these specific gene lists for the above treatments were 0.91 or better, and 
indicated all three treatments had a strong ISR (Table 2 and Supplemental Table 4).  One 
apparent difference was that the inflammatory response was weaker in the metformin treatment. 
Metformin treatment produced lower levels of mRNA induction for the CD14 antigen (CD14), 
cardiotrophin-like cytokine factor 1 (Clcf1), cyclo-oxygenase 2 (Cox2), colony stimulating factor 
1 (Csf1), MCP-1, oncostatin M receptor (Osmr), plasminogen activator inhibitor type 1 (PAI or 
Serpine1) and suppressor of cytokine signaling 3 (Socs3) genes that respond more strongly with 
t10c12 CLA treatment  (Supplemental Table 6). 
Metformin’s ability to enhance the effectiveness of a low dose of t10c12 CLA was then 
evaluated in ML and MC mice. The three-way interaction of mouse line x t10c12 CLA x 
metformin was significant for epididymal (EPI) WAT (P = 0.08) and approached significance for 
retroperitoneal (RP; P = 0.22). Within the ML mice fed t10c12 CLA, those without metformin 
had only a 3% reduction in fat pad weights and had significantly greater weights for the pair of 
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RP or EPI fat pads than mice that also received the high dose of metformin (Supplemental Fig.1 
and Table 3). The MC mice fed t10c12 CLA had a 58% reduction in WAT mass, making an 
interaction with metformin difficult to evaluate (Table 3).  
Discussion 
        T10c12 CLA causes isomer specific reductions in lipids in adipocytes and here we 
demonstrated that t10c12 CLA activated AMPK, although it is not clear if this was a direct 
activation of AMPK or an indirect activation via upstream regulatory proteins [80, 82]. The cis-9, 
trans-11 isomer  of CLA (c9t11 CLA) generally does not cause lipid loss [24], but has been 
recently reported to stimulate AMPK activity in myotubes [92]. In those studies c9t11 CLA 
alleviated the palmitate-mediated suppression of AMPK activity [92]. However, those 
investigators observed the highest levels of AMPK activity in the untreated control samples, and 
they did not present data indicating c9t11 CLA independently activated AMPK, leaving this 
issue unresolved. We used LA (cis-9, cis-12 linoleic acid) as a control fatty acid because it is an 
isomer that differs from t10c12 CLA only in the 9-cis position of the double bond. In our 
experiments, the isomer specific ability of t10c12 CLA to strongly activate AMPK in adipocytes 
correlated with its isomer-specific lipid lowering properties in adipocytes.   
AMPK’s central role in reducing anabolic biosynthesis and increasing catabolic processes 
helps explain the dramatic fat loss and variety of physiological and molecular responses 
observed in WAT in mice fed t10c12 CLA [12, 24, 50, 67]. Key metabolic or regulatory proteins 
known to be inhibited by AMPK phosphorylation include ACC, SREBP1c, C/EBPα, FAS, 
HMGR, and glycogen synthase [82, 93]. We found compound C attenuated the reduction in the 
levels of the SREBP1c, C/EBPα and PPARγ proteins and the increase in the phosphorylation of 
ACC typically caused by t10c12 CLA. Activated AMPK is also expected to phosphorylate 
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transcription co-activator p300 which should reduce its interaction with transcription factors 
PPARγ and retinoid X receptor, inhibiting their ability to induce lipogenesis [94]. The DNA 
binding activity of the transcription factor ChREBP, which regulates genes involved in 
glycolysis and lipogenesis, is also known to be inhibited when phosphorylated by AMPK [95]. 
The presence of activated AMPK in these cells and its known ability to cause reductions in the 
activity or amounts of these key biosynthetic and regulatory proteins helps explain the reduction 
in lipogenesis [71, 73, 74] and the reduced transcript levels of many lipogenic genes in t10c12 
CLA-treated adipocytes.   
An ISR is initiated by t10c12 CLA in WAT in mice and 3T3-L1 adipocytes [67].  
Increased AMPK activity was sufficient to initiate an ISR when the AMPK activator AICAR 
was added to F442a adipocytes [96]. Our microarray analysis indicated an ISR occurred in 3T3-
L1 adipocytes treated with AMPK activator metformin, whose chemical structure is unrelated to 
AICAR’s.  We also found that compound C inhibited the ability of t10c12 CLA to induce an ISR. 
Together, these results strongly suggest that activation of AMPK by t10c12 CLA is responsible 
for the ISR observed. Activation of the ISR has been observed to cause reductions in WAT of 
mice fed a leucine deficient diet [79].  This latter observation supports a functional role for an 
ISR in lipid loss in adipocytes.  
An inflammatory response occurs during the response to t10c12 CLA in vitro and in vivo 
[12, 60, 72]. Inhibition of NF-κB reduces the inflammatory response in t10c12 CLA-treated 
human adipocytes and attenuates the reduction in glucose transporter GLUT-4 and PPARγ 
protein levels [60].  We found that inhibition of NF-κB, and its associated inflammation response, 
attenuated TG reduction in t10c12 CLA-treated 3T3-L1 adipocytes.  Metformin activated AMPK, 
induced an ISR that did not induce MCP-1, and produced a weaker TG loss in 3T3-L1 
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adipocytes or in WAT in mice.  AICAR seems to repress inflammatory responses as AICAR 
reduced the production of MCP-1 from stimulated adipocytes [97]. An ISR might be sufficient to 
cause an inflammatory response through activation of NF-κB [98], but this inflammatory 
response was partially suppressed when metformin or AICAR was used in combination with 
t10c12 CLA, possibly by AMPK independent mechanisms [99]. Taken together, these results 
indicate that although some level of an inflammatory response appears to be needed for robust 
TG loss, higher levels of inflammation are not required.   
Many physiological responses are known to participate in mediating the lipid loss in 
t10c12 CLA treated adipocytes [12, 24, 50, 67] and activated AMPK may play a role in many of 
these processes [80, 82]. In particular, activated AMPK might facilitate the increased rates of 
fatty acid oxidation that occur in t10c12 CLA-treated 3T3-L1 adipocytes [70]. AMPK 
phosphorylation of ACC is expected to reduce the amount of malonyl-CoA that ACC produces. 
In addition to its role in fatty acid biosynthesis, malonyl-CoA is a key regulatory molecule that 
inhibits the activity of carnitine palmitoyltransferase-1 (CPT-1) [100]. A more active CPT-1 will 
increase the rate of fatty acid transport into mitochondria and produce an increased fatty acid 
oxidation rate [93]. Previous microarray studies of WAT of mice fed t10c12 CLA for 1 to 14 or 
17 days showed increased transcript levels of both CPT-1 and uncoupling protein 1 (UCP-1) 
after several days [12, 50]. The combination of reduced amounts of malonyl-CoA, increased 
amounts of CPT-1 fatty acid transporter activity, and higher levels of UCP-1 would support an 
increased rate of fatty acid oxidation in vivo, which is consistent with the increased rates of 
metabolism that have been observed in some experiments with t10c12 CLA-fed mice [52]. The 
much higher levels of UCP-1 mRNA observed in t10c12 CLA fed mice [12, 50] might provide a 
longer term mechanism of reducing adiposity as transgenic mice overexpressing UCP-1 in WAT 
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were found to have elevated AMPK activity levels and to be resistant to diet-induced obesity 
[101].   
The question remains as to whether activation of AMPK by t10c12 CLA is necessary to 
mediate the majority of the lipid reduction effects observed in treated adipocytes. Either AICAR 
or metformin activated AMPK in adipocytes, but produced only limited reductions in lipid levels 
relative to the reductions observed with t10c12 CLA treatments. This difference might be 
explained by our finding that t10c12 CLA more strongly activated AMPK over longer times, 
thereby increasing its effects. The ability of either AMPK activator to allow a lower 
concentration of t10c12 CLA to cause a more robust lipid loss in adipocytes further supports the 
involvement of AMPK activity with the amount of lipid lost. The complete inhibition of t10c12 
CLA-mediated TG reduction we observed on addition of compound C indicates AMPK is 
probably a key component of this response. The reduced phosphorylation of AMPK and ACC 
that occurred when treated with compound C, provided confirmation that compound C is 
inhibiting AMPK in our experiments. However, compound C could potentially inhibit other 
protein kinases that might also affect the response. This possibility of another pathway playing a 
major role in the response is not supported by our finding of very similar transcriptional 
responses to metformin, t10c12 CLA, or the combination of the two.  Altogether, these results 
are consistent with a hypothesis that activated AMPK is a necessary component of the 
mechanisms utilized by t10c12 CLA to mediate lipid loss in adipocytes.  
In tests of t10c12 CLA and metformin in mice, metformin’s enhancement of the effects 
of t10c12 CLA in ML mice was consistent with our results in 3T3-L1 adipocytes while the 
results from the MC mice were inconclusive. This is probably because the 58% loss of WAT 
mass caused by t10c12 CLA alone made further reductions in lipid amounts in the WAT more 
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difficult to achieve in MC mice.  Additionally, the MC and ML mice are not inbred lines and 
were bred to have substantial genetic variability within each line [102], possibly contributing to 
the variation in the responses observed, which reduced the statistical significance of the results. 
Our interpretation of these results is that metformin is probably more effective when combined 
with t10c12 CLA at a marginal low dose than with a higher dose of t10c12 CLA that is sufficient 
to cause robust lipid loss.  
The AMPK activators, metformin and members of the thiazolidinediones class (e.g., 
rosiglitazone and pioglitazone), are widely used in the treatment of insulin resistance and type 2 
diabetes [80, 103, 104].  These drugs activate AMPK indirectly, and partially reverse the 
decreased AMPK activity and increased malonyl-CoA levels associated with metabolic 
syndrome [105-107]. AMPK also affects the organism’s energy perception through its regulation 
by adipokines such as leptin and adiponectin [107]. Our results suggest that t10c12 CLA should 
be added to this list of chemicals used in humans that elicit mechanisms that activate AMPK. 
These results may have relevance to human trials by suggesting that t10c12 CLA’s limited 
effectiveness for reducing adiposity in humans [108] might be increased in combination with 
metformin or other dietary or medicinal chemicals that activate AMPK. However, AMPK 
activators that are also potent PPARγ agonists, such as the thiazolidinediones, are not likely to be 
as useful as they antagonize the effects of t10c12 CLA [109].  
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Tables and figures 
 
Table 1.  Levels of TG, relative levels of AMPK and ACC phosphorylation, or MCP-1 mRNA 
in 3T3-L1 adipocytes treated with AMPK activators alone or in combination with t10c12 
CLA1
 
1Differentiated adipocytes were treated with LA (-CLA) or t10c12 CLA (+CLA), 2 mmol/L 
AICAR, or 2 mmol/L metformin alone, or in combination. Data are presented as the mean ±  
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SEM, n=3 independent experiments. Means in a row not sharing a common letter differ, P ≤  
0.05. 
2TG levels were measured 24 h after treatment with 50 µmol/L of either fatty acid.  
3Immunoblots were analyzed as described in Figure 4.  
4Cells were treated with 100 µmol/L of either fatty acid for 12 h and the amounts of MCP-1 and 
GAPDH mRNA determined.
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Table 2.  Spearman correlation coefficients for gene expression changes in 3T3-L1 adipocytes 
treated with t10c12 CLA, metformin or the combination1 
____________________________________________________________________________     
                                                      ___           Treatment compared                             _                                             
Gene list compared2 Metformin  T10c12 CLA + Metformin_________                                   
 All significant genes3                                                                                                                        
t10c12 CLA 0.75 (n = 246)  0.86 (n = 410) 
t10c12 CLA + Metformin 0.92 (n = 408) 
 
ISR4 genes (n = 63) 
t10c12 CLA 0.91   0.96  
t10c12 CLA + Metformin 0.97   
 
Lipogenesis4 (n = 69) 
t10c12 CLA 0.95    0.97  
t10c12 CLA + Metformin 0.98  
___________________________________________________________________________ 
1 Data for each treatment were derived from 3 microarrays and analyzed for the Spearman 
correlation coefficient for the comparisons indicated, and had P-values ≤ 1 x 10-10.   
2The number of genes being compared in each gene list is represented by n.  
3The ‘all significant genes’ list is derived from the union of genes in either treatment that show a 
four fold change in expression and a Benjamini-Hochberg-adjusted P-value ≤  0.1 in at least one 
of the treatments being compared.   
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4The ISR and lipogenesis gene lists were derived from a list of genes previously found to be 
responsive to t10c12 CLA or tunicamycin in 3T3-L1 adipocytes [67].  
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Table 3.   The effect of combining metformin and t10c12 CLA on lipid loss in ML and MC mice1 
 
1Data are presented as mean ± SEM, n = 6. Means in a row not sharing a common superscript differ, 
P< 0.1.  
2The change in body weight (BW) or the final weight of the epididymal (EPI) or retroperitoneal (RP) 
was measured after 14 d of treatments.  
3Mice were fed diets supplemented with soy oil (-CLA), or t10c12 CLA (+CLA), and given drinking 
water lacking (Met0) or containing metformin at 2 (Met2) or 20 mmol/L (Met20) for 14 d.  
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Figure 1.  TG (A) and phosphorylated AMPK (B) and ACC (C) levels in 3T3-L1 adipocytes 
treated with t10c12 CLA, in combination with compound C (A), or alone (B, C). Differentiated 
3T3-L1 adipocytes were incubated with 100 µmol/L LA or t10c12 CLA, with or without 
compound C (Comp.C) for 24 h or the indicated times. Representative western blots indicate the 
proteins detected with antibodies to p-AMPK (p-Thr 172), total AMPK, p-ACC (p-Ser 79), or 
total ACC. Each bar represents the mean + SEM, n=3 independent experiments. Means not 
sharing a common letter differ, P ≤  0.05.  
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Figure 2.  Compound C attenuates t10c12 CLA effects on phosphorylated AMPK and ACC (A); 
ATF4 (B); ATF3 and NF-κB (C); C/EBPα, SREBP1c, and PPARγ (D); or MCP-1 mRNA levels 
(E) in 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were treated with 100 µmol/L LA (-) 
or t10c12 CLA (+), with or without compound C (Comp.C) as indicated and the cytoplasmic or 
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nuclear fractions harvested at the following times for analysis of the indicated proteins: A) 1 h 
cytoplasmic: p-AMPK, AMPK, p-ACC, ACC; B) 2 h nuclear: ATF4; C) 8 h nuclear: ATF3, NF-
κB p65; D) 12 h nuclear: C/EBPα, SREBP1c, PPARγ.   Representative western blots are shown 
for the cytoplasmic or nuclear extracts analyzed with the antibodies to the proteins indicated. 
Lamin B (Lam B) was used as a control for the amount of nuclear protein loaded for each blot in 
B, C and D, and is only shown once in each panel.  E)  The indicated treatments were for 12 h. 
MCP-1 levels and GAPDH were quantitated by real time PCR of cDNA. Each bar represents the 
mean + SEM, n=3 independent experiments. Means not sharing a common letter differ, P ≤  0.05. 
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Figure 3.  Bay 11-7082 inhibits t10c12 CLA’s ability to reduce TG levels (A), translocate NF-
kB to the nucleus (B), or induce MCP-1 mRNA levels in 3T3-L1 adipocytes (C). Differentiated 
3T3-L1 adipocytes were treated with 100 µmol/L LA (-) or t10c12 CLA (+) for 24 (A) or 12 h 
(B, C), with or without 2 µmol/L Bay11-7082 (Bay11). Representative western blots are shown 
for nuclear extracts analyzed with antibodies specific for the p65 subunit of NF-kB  or lamin B 
(Lam B).  The mRNA levels of MCP-1 and GAPDH were quantitated by real time PCR of 
cDNA.  Each bar represents the mean + SEM, n=3 independent experiments. Means not sharing 
a common letter differ, P ≤  0.05. 
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Figure 4.  AMPK activators affect the ability of t10c12 CLA to increase AMPK and ACC 
phosphorylation  in 3T3-L1 adipocytes. Differentiated adipocytes were treated with LA (-) or 
t10c12 CLA (+ or CLA), 2 mmol/L AICAR, or 2 mmol/L metformin (Met) alone, or in 
combination. Representative immunoblots are shown of proteins extracts from cells treated with 
100 µmol/L of either fatty acid for 2 or 8 h, and analyzed with antibodies to p-AMPK (p-Thr 
172), total AMPK, p-ACC (p-Ser 79), or total ACC.  Immunoblots analyses were repeated three 
times for each antibody. The data from the quantitative analysis of the immunoblots is presented 
in Table 1.  
 
 
 
 
 
Figure 5.  Metformin increases the lipid loss response to t10c12 CLA in retroperitoneal fat pads 
of ML mice. ML were fed diets supplemented with 2.5 g/kg soy oil (Control), or t10c12 CLA 
(CLA) at either 2.5 or 5 g/kg, and given drinking water lacking or containing metformin (20 
mmol/L) for 14 d. One retroperitoneal fat pad is shown for each of the 6 mice for each of the 
treatments indicated.
 Control 
2.5 g/kg CLA 
     Metformin 
5 g/kg CLA 
    2.5 g/kg CLA + Metformin 
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Chapter III. Activated AMPK and prostaglandins are involved in the response to 
conjugated linoleic acid and are sufficient to cause lipid reductions in adipocytes 
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INTRODUCTION 
        Dietary conjugated linoleic acid (CLA) causes dramatic reductions in adiposity in 
mice and in human adipocyte cultures [16, 24, 60, 69]. An active isomer for reductions in 
white adipose tissue (WAT) is the trans-10, cis-12 isomer (t10c12 CLA; [24]). The 
molecular responses to t10c12 CLA  are remarkably diverse and include the integrated 
stress response (ISR; [67, 110]) or the unfolded protein response (UPR; [76]), a nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated inflammatory 
response [60], mitogen-activated protein kinase (MAPK) cascades [57], and AMP-
activated protein kinase (AMPK) [111, 112].  
        AMPK is a central regulator of cellular energy levels that is activated by increases in 
the cellular AMP/ATP ratio, cellular processes [80, 81], and t10c12 CLA in adipocytes 
[111] or mixed isomers of CLA in mice [112].  AMPK is a heterotrimeric protein and 
activated AMPK requires phosphorylation at AMPKα threonine 172 [80, 81]. Activated 
AMPK phosphorylates acetyl-CoA carboxylase (ACC) to inhibit fatty acid biosynthesis, 
and the amount of phosphorylated ACC provides a measurement of AMPK activity in 
vivo [113]. Drugs such as 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), 
metformin, and phenformin directly or indirectly activate AMPK [80, 93], while 
compound C is a potent inhibitor of AMPK. Either AICAR or metformin is sufficient to 
initiate an ISR in adipocytes [96, 111], supporting a role for activated AMPK in this 
response. An ISR can activate NF-κB [98], and compound C blocks the ISR, activation of 
NF-κB, and NF-κB-dependent inflammatory response [60] that are induced in t10c12 
CLA treated adipocytes [111], indicating these responses are AMPK dependent. Whether 
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activation of AMPK is sufficient to explain the TG loss response caused by t10c12 CLA 
remains unresolved.  
         The inflammatory response has been proposed as a critical component of the 
triglyceride (TG) reduction that occurs in adipocytes exposed to t10c12 CLA [12, 24, 50, 
60, 67, 72]. NF-κB is required for the inflammatory response, and inhibition of NF-κB 
attenuates IL6 induction, the repression of GLUT4 and Peroxisome Proliferator-
Activated Receptor γ (PPARγ) protein activity, and the reduced glucose transport that 
otherwise occur in t10c12 CLA treated human adipocytes [60]. Inhibition of NF-κB also 
attenuates the reduction in TG levels in t10c12 CLA treated 3T3-L1 mouse adipocytes 
[111]. A key difference in the weak TG reduction that occurs in the presence of AMPK 
activator metformin, and the more robust lipid loss mediated by t10c12 CLA is the 
stronger inflammatory response that occurs with t10c12 CLA [67, 111]. The 
proinflammatory cytokine tumor necrosis factor α (TNF-α) is sufficient for lipid loss in 
adipocytes [114], and is moderately induced by t10c12 CLA in human adipocytes [60], 
but not in 3T3-L1 adipocytes [67]. PPARγ is a master regulator of adipogenesis and a key 
regulatory point for controlling inflammation in adipocytes [115].  PPARγ and NF-κB are 
mutually antagonistic, as PPARγ inhibits NF-κB transcriptional activity through 
transrepression [115], and NF-κB activity indirectly reduces PPARγ protein levels in the 
t10c12 CLA response [60].  
        T10c12 CLA increases prostaglandin (PG) biosynthesis in human adipocytes [110] 
and in mouse WAT [116]. PG biosynthesis is controlled in part by the rate-limiting 
release of arachidonic acid (AA) from the cell membrane by phospholipase A2 (PLA2). 
AA is then converted into PGH2, the precursor to the prostanoids, including the 
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prostaglandins, by either cyclo-oxygenase (COX)-1 or by the inflammation-inducible 
COX2 [117]. PG production is increased in t10c12 CLA-treated adipocytes through 
increased activation of PLA2 [110], as measured by its increased phosphorylation, and 
increased levels of COX2 mRNA [67, 110]. At least one member of the PG family, 
PGF2α, negatively affects adipocyte differentiation [118], but the functional role of 
increased PG biosynthesis in t10c12 CLA treated adipocytes has not been established.  
          The interplay between AMPK activation and the inflammatory response, 
particularly its PG component, in causing the reduction of TG levels that occurs in t10c12 
CLA treated adipocytes, is not currently well defined. The goal of this study was to test 
the following hypotheses: 1) A moderate activation of AMPK and an inflammatory 
response are sufficient to reduce triglycerides, and 2) Strong activation of AMPK is also 
sufficient. Our experimental approach was to establish the possible involvement of 
specific pathways through chemical inhibitors, confirm that these pathways are activated 
by t10c12 CLA, and then attempt to activate these pathways independently of t10c12 
CLA to functionally assay their ability to reduce TG levels in adipocytes. Our rationale 
was that independent activation of the critical pathways should produce responses similar 
to those caused by t10c12 CLA, and thereby provide additional support for the functional 
roles these pathways play.  A potent activator of AMPK was analyzed for its similarity to 
t10c12 CLA in its ability to lower TG levels, in its whole genome transcriptional 
response, and in its cell-type dependent induction of the ISR.  The results of these studies 
support our hypotheses and provide new insights into the mechanisms utilized by t10c12 
CLA to reduce TG levels in adipocytes.  
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METHODS AND MATERIALS 
Reagents.  Arachidonic acid, bovine serum albumin (BSA, > 99% fat free), CP-24879, 
dexamethasone, Ibuprofen, insulin, isobutyl-1-methylxanthine, metformin, Naproxen, 
PGE2, phenformin and TNF-α were from Sigma (St. Louis, MO). AMPK inhibitor 
compound C was purchased from Calbiochem (San Diego, CA). Antibodies to p-AMPK 
(α1 and α2), AMPK (α1 and α2), p-ACC (ACC1 and ACC2), ACC (ACC1 and ACC2), 
p-PLA2, and PLA2 were from Cell Signaling (Beverly, MA). PGF2α, PGH2, SP600125, 
and U0126 were from Fisher (Pittsburgh, PA).  
3T3-L1 cell culture and differentiation. 3T3-L1 fibroblasts [85] were cultured in 
Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) containing 
25mM glucose and 10% bovine calf serum (Fisher, Pittsburgh, PA) and differentiated as 
described [86]. In brief, two days after growing to confluence, the cells were induced to 
differentiate in DMEM containing 25mM glucose and 10% fetal bovine serum (FBS; 
Fisher, Pittsburgh, PA), 0.17 µmol/L insulin, 0.5 mmol/L isobutyl-1-methylxanthine, and 
1 µmol/L dexamethasone for 3 days. The medium was then changed to 10% FBS/DMEM 
containing 25mM glucose and with 0.17 µmol/L insulin for another 2 days, at which time 
the cells were usually differentiated to at least 90% adipocyte, followed by basal 10% 
FBS/DMEM medium containing 25mM glucose before initiating fatty acid treatments. 
All media contained 100,000 U/L penicillin and 172 µmol/L streptomycin (Invitrogen, 
Carlsbad, CA).  
Fatty acid treatments. Fatty acids (>99%, Nu-check Prep, Elysian, MN), either linoleic 
acid or trans-10, cis-12 CLA, were dissolved in 0.1 M KOH, diluted into fatty acid free 
(>99%) bovine serum albumin (BSA) in phosphate buffered saline at a 1:1 ratio (2 
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mmol/L BSA: 2 mmol/L fatty acid), pH adjusted to 7.4, and added to the cultures 
containing 5.5 to 6 d post-differentiated 3T3-L1 adipocytes.  
Western blots. Nuclear and cytosolic extracts were isolated based on the manufacturer's 
protocol (Active Motif, Carlsbad, CA). Equal amounts of proteins were separated by 
SDS-PAGE, transferred to Immun-blot PVDF membrane (Bio-Rad Laboratories, 
Hercules, CA) and probed with the indicated antibodies. Enhanced chemiluminescence 
(Pierce, Rockford, IL) was used for detection. Band intensities were determined from 
digital images from exposures in the linear range using imaging software (Quantity One, 
Biorad, Hercules, CA). All western blot analyses were repeated at least three times. 
Quantification of TG content. Cell isolation and TG measurements were performed 
according to the manufacturer using TG reagent (T2449; Sigma, St. Louis, MO) and free 
glycerol reagent (F6428; Sigma, St. Louis, MO). Protein concentrations were measured 
using Bradford dye (Biorad, Hercules, California) to obtain results as µg of TG per mg of 
protein.  
Measurement of PGF2α. Cell culture concentrations of PGF2α were determined using 
culture media samples obtained immediately prior to cell harvest for TG analysis. PGF2α 
levels were measured by enzyme immunoassay (EIA) using the Correlate-EIA PGF2α 
Kit (Assay Designs, Ann Arbor, MI) according to the manufacturer's instructions. A 
standard curve was plotted using dilutions of a known concentration of the PGF2α 
standard, and sample concentrations were determined based on this standard curve. Data 
were derived from three independent experiments, with two replicates in each experiment. 
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Real time PCR analysis of cDNA from mRNA. Total RNA was extracted by TRIzol 
(Invitrogen) following the manufacturer’s protocol. Total RNA (2 µg) was used for 
cDNA synthesis. Real-time PCR was performed by a Bio-Rad iCycler using iQ SYBR 
Green Supermix reagent (Bio-Rad, Hercules, CA). The primer sequences for MCP-1 and 
GAPDH were taken from [87], and all other primer sequences of genes analyzed by real 
time PCR are shown in Supplementary Table 5. The cDNA levels were normalized to 
GAPDH, which showed no significant variation in microarrays between LA and t10c12 
CLA treatments. Experiments were repeated three times, and each sample was analyzed 
using one RNA control and two replicates of each cDNA pool, and the relative amounts 
of each target cDNA and GAPDH were calculated using the comparative CT method 
[according to the manufacturer’s software (Bio-Rad, Hercules, CA) and [88]]. Cycle 
numbers were used to calculate gene expression levels in the linear amplification range, 
and qRT-PCR efficiency was close to 100%. 
Microarray data analysis. RNA isolation and labeling of the 3T3-L1 adipocytes was 
performed as previously reported [67]. Results of the treatments of each of the three 
biological replicates were collected from Affymetrix® GeneChip Mouse Genome 430 2.0 
arrays via the Affymetrix GeneChip Operating Software (GCOS; Affymetrix, Santa Clara, 
CA). The raw data for microarray results were normalized using the methods described 
by Wu et al [89]. To identify differentially expressed genes between the control (linoleic 
acid) and other treatments, the linear models for microarrays [Limma; [90]] package in 
R/Bioconductor was used, with Benjamini-Hochberg [119] adjusted P-values. Those 
genes with an absolute log2 ratio of 2 or more (four-fold up- or down-regulated) and a 
Benjamini-Hochberg adjusted P-value≤ .05 were deemed to be significant and analyzed 
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further. The gene expression data has been deposited at the NCBI Gene Expression 
Omnibus with series number GSEXXXXX (access activated upon publication). 
Statistical Analysis.  
Experiments represented in Figures 1 through 6 were subjected to analysis of variance 
using fixed effect statistical models.  F-statistics, least-squares means, and standard errors 
were calculated using software of SAS (Cary, NC). The main effects or interactions were 
considered significant if P≤ .05, unless otherwise noted. For Fig. 1A, the main effects of 
TNF-α (0, 0.1, 0.3 or 0.6 nmol/L) and Met (- or +), and their interaction (TNF-α x Met) 
were analyzed. For Fig. 1B, the main effects of TNF-α (- or +) and compound C (- or +), 
and their interaction (TNF-α x Comp.C) were determined. The data presented in each 
panel of Fig. 2 were analyzed using a statistical model that included a single main effect.  
For Fig. 3, the main effects of CLA (- or +) and Ibuprofen (- or +), Naproxen (- or +) or 
CP-24879 (- or +), and their interaction (CLA x Ibuprofen, Naproxen or CP-24879) were 
separately determined for both the TG and PGF2α experiments. For Fig. 4, the main 
effects of Met (- or +) and PGE2 (- or +), PGF2α (- or +), PGH2 (- or +), or AA (- or +) 
and their interaction (Met x PGE2, PGF2α, PGH2 or AA) were separately determined. 
For Fig. 5A, the main effects of CLA (- or +) and time (2, 4, 8, and 12 h), and their 
interaction (CLA x time) were determined. For Fig. 5B and 5C, the main effects of CLA 
(- or +) and SP600125 (- or +) or U0126 (- or +), and their interaction (CLA x SP or 
U0126) were determined. For Fig. 6, the large range of the response values of ATF3 
required both a log10 transformation and separating the data into a first group (panel A) 
and second group (panel B). The main effects of CLA (- or +), phenformin (- or +), and 
day (-2, 0, 1-5 d), and their interaction (CLA or Phen x d) were determined. Individual 
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pairwise comparisons of least-squares means were calculated by Least Significant 
Difference Test. Data are presented as least-squares means + SEM. Means not sharing a 
common superscript differ significantly (P≤ .05), unless otherwise noted.  
RESULTS 
          Our hypothesis, based on prior use of chemical inhibitors, was that moderate 
activation of AMPK and an inflammatory response are sufficient to reduce TG levels in 
adipocytes. This was tested independently of t10c12 CLA as follows. Metformin was 
used to activate AMPK, as it was found previously to moderately activate AMPK without 
initiating a strong inflammatory response [111]. TNF-α, an inflammatory cytokine 
capable of causing reductions in TG levels in adipocytes [114], was used at several 
concentrations as the inflammatory stimulus. As a control, the biological activity of the 
TNF-α sample was separately verified in adipocytes by its induction of MCP-1 and 
CXCL1 mRNAs (Supplemental Fig.1), which were induced to levels similar to those 
caused by treatments with t10c12 CLA (data not shown). Either metformin or 0.6 nmol/L 
TNF-α caused reductions in TG levels of 14 ± 2% or 19 ± 4%, respectively (Fig. 1A).  
The reduction in TG levels was 40 ± 4% when both metformin and 0.6 nmol/L TNF-α 
were used in combination (Fig. 1A).  
         This result appeared to support our hypothesis, and to further strengthen this 
analysis, we checked whether the response to TNF-α was dependent on activated AMPK. 
Surprisingly, when the AMPK inhibitor compound C was tested for its ability to inhibit 
the TG loss caused by TNF-α alone, the majority of the TNF-α mediated reduction in TG 
was attenuated (Fig. 1B). This latter result indicated the above experiments had more 
relevance for our second hypothesis that higher levels of activated AMPK were sufficient 
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to cause robust TG loss. This hypothesis was separately tested by using phenformin, a 
more potent AMPK activator that is structurally related to metformin. Phenformin was 
used at increasing concentrations, which resulted in progressively lower TG levels (Fig. 
2A). 100 µmol/L phenformin was able to reduce TG levels by 45 ± 5%, nearly the same 
reduction as achieved by 100 µmol/L t10c12 CLA (50 ± 2%; Fig. 2A).   
         To gain further insight into the association of the amount of activated AMPK with 
reduced TG levels and inflammation, the ability of TNF-α, phenformin, metformin, or 
t10c12 CLA to activate AMPK, reduce TG levels, and induce COX2 mRNA was 
measured.  Each of these chemicals increased phosphorylation of AMPK, as well as of 
ACC, a known in vivo substrate of AMPK (Fig. 2B).  Phenformin and t10c12 CLA 
produced more phosphorylated AMPK and ACC than TNF-α or metformin at the 
concentrations used for each compound (Fig. 2B). The effects of these compounds on 
concurrent changes in TG levels and inflammation, using COX2 mRNA as an indicator 
of inflammation, was also measured (Fig. 2C). The effects of these treatments suggested 
the amounts of activated AMPK and COX2 mRNA both affected TG levels.  T10c12 
CLA or phenformin caused higher activation of AMPK and more TG loss than 
metformin or TNF-α.  Within the t10c12 CLA and phenformin treatments, t10c12 CLA 
induced higher levels of COX2 mRNA and lost more TG despite its lower amount of 
activated AMPK.  Within the metformin and TNF-α treatments, TNF-α induced higher 
levels of COX2 mRNA and lost more TG than metformin despite its lower amount of 
activated AMPK. Taken together, this data showed a trend of more highly activated 
AMPK causing more TG loss. For treatments with somewhat similar AMPK activation 
levels, higher COX2 mRNA levels seemed to be associated with more TG loss.  
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         This latter observation supported a hypothesis that PGs might be a critical 
component of the inflammatory response to t10c12 CLA. The functional role of PGs was 
then investigated by using chemicals that inhibit PG production. Treatment of 3T3-L1 
adipocytes with Naproxen, Ibuprofen, or CP-24879 (an inhibitor of AA biosynthesis) 
inhibited the ability of t10c12 CLA to cause TG reductions (Fig 3A).  The effectiveness 
of these chemicals in reducing PG levels, using PGF2α levels as an indicator of PG 
production, was then determined (Fig 3B).  The modest reductions of PGF2α levels by 
Naproxen or Ibuprofen treatments were not significant, while CP-24879 caused a 
significant reduction in PGF2α in t10c12 CLA treated adipocytes (Fig 3B).  The 
effectiveness of these inhibitors at reducing PGF2α levels was in agreement with their 
effectiveness at attenuating the TG loss caused by t10c12 CLA (Fig 3A).  
          The functional importance of PG in the TG reductions in t10c12 CLA treated 
adipocytes generated an alternative to TNFα for providing an inflammatory stimulus to 
test our first hypothesis (a moderate activation of AMPK and an inflammatory response 
are sufficient to reduce TG levels in adipocytes) independently of t10c12 CLA. This 
hypothesis was tested by adding a combination of metformin and a PG or AA, a 
precursor to PG biosynthesis, to 3T3-L1 adipocytes. Metformin alone produced a 15 ± 
4% reduction in TG levels (Fig. 4), while t10c12 CLA reduced TG levels by 47 ± 5% 
(data not shown). PGE2 alone had no effect, while the combination of PGE2 and 
metformin increased the amount of TG (Fig. 4). PGF2α alone reduced TG levels by 6 ± 
2%, while PGF2α and metformin caused a 32 ± 7% TG loss (Fig. 4). PGH2 alone had no 
effect on TG levels, while the combination of PGH2 and metformin reduced TG levels by 
41 ± 2% (Fig. 4). Similarly, AA alone had no effect, while AA and metformin reduced 
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TG levels by 45 ± 7% (Fig. 4). Metformin combined with PGH2 or AA was nearly as 
effective as t10c12 CLA in causing reductions of TG levels in these experiments, 
providing support for our first hypothesis, where the inflammatory component is supplied 
by exogenous PGH2 or AA.  
          The mechanism by which PG production is regulated in t10c12 CLA treated 
adipocytes was then investigated. PLA2 releases AA by hydrolysis from the glycerol 
backbone of membrane lipids. PLA2 activity is activated by phosphorylation, and its 
phosphorylation has been reported to be increased by t10c12 CLA in human adipocytes, 
with the possible involvement of ERK and JNK [110]. The involvement of the ERK and 
JNK signaling pathways in the activation of PLA2 by phosphorylation was therefore 
examined.  Increasing amounts of phosphorylated PLA2 were observed during longer 
times of exposure to t10c12 CLA (Fig. 5A).  The phosphorylation of PLA2 was found to 
be reduced in the presence of JNK inhibitor SP600125 or MEK inhibitor U0126 (Fig. 5B), 
both of which also inhibited t10c12 CLA’s ability to reduce TG levels (Fig. 5C).    
         The abilities of t10c12 CLA and phenformin to strongly activate AMPK and to 
cause robust reductions in TG levels suggested phenformin might initiate cellular 
responses very similar to those caused by t10c12 CLA. Our hypothesis was that if similar 
signaling pathways were being utilized by the two chemicals, the microarray results 
should show a high degree of similarity when analyzed for their correlation coefficients. 
Microarray analysis generated a list of genes with changes in transcript levels of at least 
4-fold in either t10c12 CLA- or phenformin-treated adipocytes (Supplementary Table 1).  
Previous lists of genes that responded to t10c12 CLA in the ISR, lipid metabolism, or 
inflammatory pathways [67] were also used to compare the changes in the two treatments 
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(Supplementary Tables 2-4). These lists were separately analyzed for the Spearman 
correlation coefficients and each comparison indicated a strong similarity between the 
transcriptional responses of 3T3-L1 adipocytes treated with phenformin or t10c12 CLA 
(Table 1). The changes in expression of selected functionally relevant genes were 
checked by real time PCR and were in good agreement with the microarray results (Table 
2).  
         Our earlier report indicated that differentiated adipocytes responded more robustly 
than their non-differentiated fibroblast precursors to t10c12 CLA, as measured by ATF3 
mRNA, an indicator of the ISR [67]. The ISR is an early component of the response to 
t10c12 CLA and can occur in both cell types [67], unlike the TG accumulation that is 
specific for maturing or mature adipocytes. This differential response in differentiated 
adipocytes provided an additional method to compare the similarities in the responses 
caused by phenformin or t10c12 CLA. Additionally, phenformin is a highly polar, water-
soluble small molecule, while t10c12 CLA is a hydrophobic fatty acid, providing an 
additional test as to whether the hydrophobic or hydrophilic nature of the chemical 
affected the response of cells at different differentiated states. The competence of  a 
developmental series consisting of 3T3-L1 fibroblasts, differentiating adipocytes, and 
mature adipocytes to respond to phenformin or t10c12 CLA was measured by the 
induction of ATF3 mRNA as an indicator of the ISR. The abilities of phenformin or 
t10c12 CLA to induce ATF3 were similar and increased dramatically at about 3 d after 
differentiation, with the highest levels induced at 4 and 5 d after differentiation when 
young and maturing adipocytes were present (Fig. 6). The developmental competence to 
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respond to both chemicals appeared to be the same, strengthening the premise that both 
chemicals activated the same developmentally-regulated pathways.  
DISCUSSION 
          We examined the contributions the AMPK and inflammatory pathways, 
particularly PGs, make towards reducing TG levels in t10c12 CLA treated adipocytes. A 
key part of our approach was to activate these pathways independently of t10c12 CLA to 
assess their contributions away from the complex response initiated by t10c12 CLA [12, 
24, 67]. However, the interpretation of these “chemical mimicry” studies also relies on 
the fact that these pathways are activated by, and their inhibition attenuates the response 
to, t10c12 CLA. These chemical mimicry studies benefited from metformin’s ability to 
moderately activate AMPK without producing a strong inflammatory response in 
adipocytes [111], and phenformin’s ability to strongly activate AMPK and an 
inflammatory response as demonstrated here. TNF-α, a pro-inflammatory cytokine, was 
initially used to increase the inflammatory response in adipocytes treated with metformin. 
TNF-α negatively regulates AMPK activity in muscle cells [120], and the extent to which 
TNF-α relied on AMPK activation to mediate TG reductions in adipocytes was 
previously unclear [114, 121]. Our data indicated TNF-α’s major contribution to reducing 
TGs appeared to be through activated AMPK as TNF-α treated adipocytes had increased 
AMPK activity, and the majority of TNF-α’s ability to reduce TG levels was inhibited by 
compound C. TNF-α’s activation of AMPK confounded the interpretation of its 
contribution to the inflammatory response, but proved useful as one of several treatments 
we used to establish a correlation of AMPK activity levels with TG reductions.  
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          In addition to the level of activated AMPK, the amount of TG reduction also 
appeared to be influenced by the level of induction of COX2 mRNA, which supported a 
role for PGs in facilitating TG reductions. PG levels increase in t10c12 CLA treated 
human adipocytes [110], mice [116], and 3T3-L1 adipocytes as demonstrated here. Much 
of the mechanism of the increased production of PGs can be explained by the activation 
of PLA2 [110] to increase AA production, the substrate for COX2, and the induction of 
COX2 mRNA levels [67, 110]. Inhibitors of MEK or JNK interfered with t10c12 CLA’s 
ability to reduce TG levels, and reduced phosphorylation of PLA2, indicating the MEK 
and JNK pathways are involved in regulating PLA2. This is in agreement with earlier 
findings of the involvement of the MEK and JNK pathways in the t10c12 CLA response 
in human adipocytes [57, 110]. Other inhibitors that interfered with either AA or PG 
biosynthesis also inhibited the t10c12 CLA-mediated reduction in TGs in adipocytes. 
These results provided support for a functional role for PGs in lowering TG levels in 
t10c12 CLA treated adipocytes.  
          The functional role of the PGs was verified independently of t10c12 CLA by 
testing them in the presence of metformin. We found metformin combined with either 
PGH2 or AA was nearly as effective as t10c12 CLA at reducing TG levels. Importantly, 
PGH2 and AA did not significantly reduce TG levels when used alone, which suggested 
activated AMPK was necessary for them to enhance the TG reduction response. If we 
make the assumption that AMPK and PGs have similar biological activity in the t10c12 
CLA-treated and alternatively-treated adipocytes, then these two components account for 
most of the TG reduction that occurs. These results support our hypothesis that a 
moderate activation of AMPK and an inflammatory response are sufficient to reduce 
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triglycerides, where most of the requirement for an inflammatory component can be 
provided by increased levels of PGs.  
          The similar effectiveness of PGH2, the precursor to the prostanoid family, and AA, 
the precursor to the entire eicosanoid pathway, suggests prostanoids play the major role 
in the response, without ruling out minor contributions from the leukotriene component 
of the eicosanoid pathway. The combination of PGF2α and metformin was not quite as 
effective.  This could be due to the participation of other eicosanoids or prostanoids 
derived from AA or PGH2, respectively, or possibly a more rapid metabolic degradation 
of exogenous PGF2α [122]. PGE2 in combination with metformin resulted in increased 
TG levels. PGE2 can be a precursor to PGF2α, but this conversion might not be efficient 
with exogenously added PGE2. Consistent with these effects, PGF2α indirectly 
suppresses PPARγ activity [118], while PGE2 can also be a precursor to 15-keto-PGE2, 
an agonist of PPARγ [123], which would be expected to oppose the effects of t10c12 
CLA [109].  
           Phenformin was sufficient to cause a robust reduction in TG levels comparable to 
the reduction caused by t10c12 CLA, supporting our second hypothesis that strong 
activation of AMPK is sufficient for TG loss. This hypothesis is consistent with the first 
hypothesis that moderate AMPK activation and an inflammatory response are sufficient 
for robust TG loss, as stronger activation of AMPK is accompanied by a stronger 
inflammatory response as described here. We previously reported the transcriptional 
responses to metformin or t10c12 CLA were also very similar, but metformin caused a 
weaker inflammatory response than t10c12 CLA [111]. The inability of metformin to 
cause the robust reductions in TG levels that result from t10c12 CLA treatments, left 
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open the question of whether t10c12 CLA activated other critical pathways or whether its 
stronger activation of AMPK was sufficient to explain the response to t10c12 CLA. The 
results with phenformin, a more potent activator of AMPK, indicate highly activated 
AMPK is sufficient to cause a larger inflammatory response than metformin, although 
still less than that caused by t10c12 CLA, that in combination with its ability to strongly 
activate AMPK, can result in a robust TG reduction.  
         A detailed microarray analysis of the transcriptional response of the individual 
genes and pathways in 3T3-L1 cells and mice WAT treated with t10c12 CLA was done 
previously [12, 50, 67].  These analyses identified increases in uncoupling protein (UCP)-
1 and carnitine palmitoyltransferase-1 (CPT1) transcripts, suggesting increased fatty acid 
oxidation could be occurring as has been observed in CLA-fed mice mice [52].  Fatty 
acid oxidation would be expected to be further enhanced by AMPK’s phosphorylation of 
ACC, reducing the malonyl CoA pool, which typically inhibits CPT1 transport of fatty 
acids into mitochrondria [124]. Microarray analyses also identified a large increase in 
many inflammatory cytokines, and moderate reductions in key adipogenic transcription 
factors including PPARγ, CCAAT/Enhancer Binding Protein α (C/EBPα), and Sterol 
regulatory element binding protein (SREBP)-1c, suggesting reduced rates of lipid and 
cholesterol biosynthesis would result. Activated AMPK should further reduce 
biosynthesis by reducing the activity of key enzymes involved in the biosynthesis of fatty 
acids, cholesterol, glycogen, and proteins [124]. Our comparison of the transcriptome 
response of adipocytes treated with t10c12 CLA or phenformin found the changes in 
overall gene expression were very similar to those changes observed previously, 
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particularly induction of the ISR, reduction in mRNAs of genes encoding regulatory and 
enzymes in the lipid biosynthesis, and induction of inflammatory pathways.   
          Within this overall strong similarity of the transcriptional responses, the most 
apparent differences were t10c12 CLA’s stronger induction of the immediate early genes 
and of some of the inflammatory response genes. The immediate early genes are a group 
of genes that are predominantly transcription factors and other signaling molecules that 
are induced by a large variety of cellular stresses [125]. Their higher induction in t10c12 
CLA treated adipocytes indicates that t10c12 CLA either causes a more general cell 
stress than phenformin or alternatively, specifically activates this pathway by an 
unknown mechanism.  In the inflammatory response, the genes induced to higher levels 
in response to t10c12 CLA included COX2, suppressor of cytokine signaling 3 (SOCS3), 
cardiotrophin-like cytokine factor 1 (CLCF1) in the IL6 cytokine family, tumor necrosis 
factor receptor superfamily member 12a (TNFRSF12a), and oncostatin M receptor 
(OSMR). The highly induced COX2 plays an important functional role in reducing TG 
levels through producing PGs as demonstrated here. SOCS3 mediates local insulin 
resistance through inhibition of insulin receptor substrate (IRS)-1 and IRS2 [126], and 
can be induced by cardiotrophin [127], and therefore, possibly by CLCF1. TNFRSF12a 
and OSMR are receptors for members of the TNFα or IL6 family of cytokines.  Although 
the levels of TNF-α and IL6 mRNAs are low in 3T3-L1 adipocytes, other family 
members of these cytokines may signal through these receptors. Despite the overall 
strong similarity of the transcriptional responses to phenformin and t10c12 CLA, they 
were not identical, and this could be due to differences between phenformin’s ability to 
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indirectly activate AMPK by inhibition of complex 1 of the mitochondrial respiratory 
chain [128, 129], and the still unknown pathways used by t10c12 CLA to activate AMPK. 
         The role of PGs in vivo may be less important as COX2 mRNA levels increased 
only 2 to 3 fold in 24 h in WAT of mice fed t10c12 CLA [12, 67]. COX2 mRNA levels 
then decreased to about control levels on subsequent days [12]. This is considerably less 
than the 8-fold or 12- to100-fold observed in human [110] and mouse adipocytes [67], 
respectively.  PGE2 levels were previously found to be increased about 3.4 fold in WAT 
of mice fed t10c12 CLA for two weeks. In that study, inhibition of PG production with 
aspirin prevented this increase in PG levels without reducing the effect of t10c12 CLA on 
WAT [116]. This suggests the role of PG in WAT might be less important in vivo than in 
adipocyte cultures. The initial and subsequent inflammatory response to t10c12 CLA 
treatment is much more robust and diverse in WAT than in adipocytes in culture [67], in 
part due to the multiple types of cells in WAT, as well as the increased infiltration of 
macrophages [72]. The relative contributions of these diverse inflammatory pathways to 
reducing WAT in vivo are unclear and require additional investigation.  
         Despite the effectiveness of t10c12 CLA, phenformin, and even metformin to a 
lesser extent, in reducing TG levels in mouse adipocytes, and t10c12 CLA’s effectiveness 
in mice [24] and primary human adipocytes [60], these chemicals have limited abilities to 
reduce adiposity in humans. The limited effectiveness of t10c12 CLA in humans remains 
unexplained [108], despite t10c12 CLA’s preferential accumulation in adipose tissue 
[130]. Phenformin is no longer used to treat type 2 diabetes due to a higher frequency of 
lactic acidosis than occurs with metformin [131, 132], and it did not reduce weight in 
non-diabetic patients [133]. Metformin is important in the treatment of type 2 diabetes, 
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but it has a limited ability to either reduce weight or inhibit weight gain in patients 
without type 2 diabetes [134]. Our finding of a correlation of the amount of activated 
AMPK with the amount of TG reduction in 3T3-L1 adipocytes, supports a hypothesis 
that higher levels of activated AMPK are needed in adipocytes for effective reduction of 
adiposity in humans. It is unclear how to best accomplish this, although direct AMPK 
activators are promising [135], and our demonstration of the differential sensitivity of 
adipocytes to AMPK activators increases the potential for cell selectivity in this approach. 
We recently demonstrated metformin increases the ability of a moderate dose of t10c12 
CLA to reduce WAT in mice [111], suggesting combinations of chemicals that activate 
AMPK are another possible approach. Adding a compound that leads to higher 
prostanoid levels in adipocytes might also be possible, but the complex biological 
responses to members of the prostanoid pathway [122, 136] indicate considerable 
research will be required to determine if this is possible in mice, and whether it can be 
accomplished in a therapeutically acceptable manner.  
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Tables and figures 
 
Table 1. Spearman correlation coefficients for gene expression changes in treatments 
containing t10c12 CLA or phenformin  
______________________________________________________________________  
Correlation coefficient 
All significant genes (n = 541)                    0.83  
ISR genes (n = 63)                                       0.87  
Lipid metabolism (n = 69)                           0.95  
Inflammation (n = 49)                                  0.85  
______________________________________________________________________  
 
Each treatment contained three replicates. The number of genes being compared is 
represented by n. For the ‘all significant genes’ the gene list is derived from the union of 
genes in either treatment that show a four fold change in expression and a Benjamini-
Hochberg-adjusted P-value ≤.05 in at least one of the treatments being compared. The 
ISR, lipogenesis, and inflammation gene lists were derived from a list of genes 
previously found to be responsive to t10c12 CLA or tunicamycin in 3T3-L1 adipocytes. 
The Spearman correlation was used with associated P-values ≈ 0. 
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Table 2. Quantitative real time PCR verification of selected genes 
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Figure 1. TNFα increases the ability of metformin to reduce TG levels in adipocytes.  
A) 3T3-L1 adipocytes were untreated or treated with either 2 mmol/L metformin (Met), 
the indicated amounts of TNF-α, or combinations of these compounds, and TG levels 
were measured after 24 h. The effects of metformin and TNF-α were statistically 
significant, but their interaction was not. B) 3T3-L1 adipocytes were either untreated or 
treated with 0.6 nmol/L TNF-α, 10 µmol/L compound C (Comp.C), or the combination, 
and TG levels were measured after 24 h. Their interaction was significant. Each bar 
represents the mean + SEM (n=3) of three independent experiments.  
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Figure 2. Phenformin causes robust delipidation and highly activates AMPK.  
A) 3T3-L1 adipocytes were treated with the indicated concentrations of phenformin, and 
TG levels were measured after 24 h. For comparison, the TG levels for adipocytes treated 
with either 100 µmol/L LA or t10c12 CLA are also shown. B) 3T3-L1 adipocytes were 
treated with 100 µmol/L LA, 0.6 nmol/L TNF-α, 2 mmol/L metformin (Met), 100 
µmol/L phenformin (Phen), or 100 µmol/L t10c12 CLA for 12 h.  Cellular extracts were 
immunoblotted and the amounts of AMPK (α1 and α2), p-AMPK (α1 and α2), ACC 
(ACC1 and ACC2), and p-ACC (ACC1 and ACC2) were determined with specific 
antibodies. The immunoblots shown were representative of three independent 
experiments. The ratios of the phosphorylated form (p-AMPK or p-ACC) to the total 
amount of each respective protein (AMPK or ACC) were determined and are shown in 
the bar charts above the immunoblots. C) The same treatments were used to determine 
their effects on TG levels after 24 h. Both the p-AMPK/AMPK ratio from B and the fold 
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induction of Cox2 mRNA at 12 h, as measured by quantitative PCR, are shown below the 
graph. The mean + SEM (n=3) of three independent experiments is shown for each type 
of measurement.   
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Figure 3. Inhibitors of prostaglandin biosynthesis inhibit the reduction in TG levels 
and increase in PGF2α levels caused by t10c12 CLA.  
A) 3T3-L1 adipocytes were treated with 100 µmol/L LA (-) or 100 µmol/L t10c12 CLA 
(+), with or without either 50 µmol/L Ibuprofen (Ibu), 200 µmol/L Naproxen (Naprox), 
or 50 µmol/L CP-24879, and TG levels were measured after 24 h. The interactions of 
t10c12 CLA with Naproxen, or CP-24879 were significant, while the interaction with 
Ibuprofen approached significance (P ≤ .08). B) Media from treatments of A were 
analyzed for PGF2α concentrations. The interaction of t10c12 CLA with Ibuprofen or 
Naproxen was not significant, but was significant for CP-24879. Each bar represents the 
mean + SEM (n=6) of three independent experiments.  
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Figure 4. Prostaglandins affect metformin’s ability to reduce TG levels. 3T3-L1 
adipocytes were treated with or without 2 mmol/L metformin (Met), and with or without 
a prostaglandin (25 µmol/L PGE2, 25 µmol/L PGF2α, or 1 µmol/L PGH2) or arachidonic 
acid (150 µmol/L AA). TG levels were measured after 24 h. The interaction of metformin 
with PGE2, PGH2, or AA was significant, but was not significant for PGF2α. Each bar 
represents the mean + SEM (n=3) of three independent experiments.  
 
   
66
 
Figure 5. T10c12 CLA induces PLA2 phosphorylation through the JNK and ERK 
pathways.  
A) PLA2 phosphorylation was measured at various times during exposure to t10c12 CLA 
in 3T3-L1 adipoctyes. The amount of phosphorylated PLA2 (p-PLA2) and total PLA2 
was determined by immunoblots with specific antibodies. The ratio of p-PLA2 to the 
total PLA2 was determined and is shown in the bar chart above the immunoblots. The 
effects of t10c12 CLA and time were significant, but their interaction was not significant. 
B) 3T3-L1 adipocytes were either not treated or pretreated for 1 h with 20 µmol/L of 
JNK inhibitor SP-600125 (SP) or 20 µmol/L of MEK inhibitor U0126.  Either 100 
µmol/L LA or 100 µmol/L t10c12 CLA was then added for 12 h. Cellular extracts from 
these treatments were analyzed by immunoblot as in A. The ratio of p-PLA2 to the total 
PLA2 was determined and is shown in the bar charts above the immunoblots. Both SP-
600125 and U0126 had a significant inhibitory interaction with t10c12 CLA. C) 
Adipocytes were treated as in B and TG levels were measured after 24 h. Both SP-
600125 and U0126 had a significant inhibitory interaction with t10c12 CLA. The 
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immunoblots shown in A and B are representative of three independent experiments, and 
each bar represents the mean + SEM (n=3) of three independent experiments.  
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Figure 6. The ability of phenformin or t10c12 CLA to induce the ISR is dependent 
on the stage of differentiation. 3T3-L1 cells at various developmental stages, either 
fibroblasts (two days before confluence; -2), differentiating adipocytes (from confluence 
(0) to five days post-confluence (days 1-5)), were treated with 100 µmol/L LA (-), 100 
µmol/L phenformin (Phen), or 100 µmol/L t10c12 CLA (CLA). RNA was isolated from 
the cells after 12 h of treatment and analyzed for ATF3 and GAPDH mRNA levels by 
reverse transcription and quantitative PCR. The relative amounts of ATF3 mRNA are 
shown as bar graphs.  Note the change in the scale of the log10 y-axis starting at day 2. 
The effects of the treatments and interactions were not significant for A. For B, the main 
effects of t10c12 CLA, phenformin, and day of differentiation and their interaction (CLA 
or Phen x d) were significant. Each bar represents the mean + SEM (n=4) of four 
independent experiments. 
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Chapter IV. Cross regulation of Sirtuin 1, AMPK, and PPARγ in conjugated linoleic 
acid treated adipocytes 
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Introduction 
           Conjugated linoleic acid (CLA) reduces adiposity in human and mouse adipocytes 
[16, 24, 60, 69], and the trans-10, cis-12 CLA (t10c12 CLA) isomer is capable of causing 
this response [137]. The rates of fatty acid oxidation and lipolysis increased in t10c12 
CLA-treated 3T3-L1 adipocytes [70], while t10c12 CLA reduced fatty acid oxidation 
[138], but increased lipolysis in human adipocytes [57]. Molecular responses to t10c12 
CLA include AMP-activated protein kinase (AMPK) [111], integrated stress response 
(ISR; [67, 110]) or unfolded protein response (UPR; [76]), mitogen-activated protein 
kinase (MAPK) cascades [57], a nuclear factor kappa-B (NF-κB)-mediated inflammatory 
response [12, 24, 50, 60, 67, 72] that includes increased prostaglandin biosynthesis in 
human adipocytes [110] and in mouse white adipose tissue [116],  and reduced amounts 
of peroxisome proliferator-activated receptor γ (PPARγ) protein [60]. Despite this 
progress, the understanding of the pathways involved in the initial perception of t10c12 
CLA, and the complex regulation of the subsequent responses, is incomplete.  
          AMPK is a central regulator of cellular energy levels that is activated by increases 
in the cellular AMP/ATP ratio, various cellular stresses [80, 81], or treatment of 
adipocytes [111] or mice [139] with t10c12 or mixed isomers of CLA. AMPK activation 
requires phosphorylation at Thr172 [135], and two of the proteins inhibited by 
phosphorylation by activated AMPK are acetyl CoA carboxylase (ACC), and fatty acid 
synthase, two key enzymes in fatty acid biosynthesis. Through this and other mechanisms 
[80, 81], activated AMPK decreases lipogenesis, increases fatty acid oxidation, and 
increases lipolysis in adipocytes in vitro and in vivo after an initial delay [140]. 
Phenformin and metformin are structurally related chemicals that can be used to activate 
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AMPK [80, 141]. Metformin increases the TG loss, while compound C, a potent inhibitor 
of AMPK, strongly attenuates the TG loss typically caused by t10c12 CLA in adipocytes 
[111].  
          PPARγ is a ligand-activated nuclear receptor that regulates lipogenesis and is a key 
regulatory point for controlling inflammation in adipocytes [115]. PPARγ forms a 
complex with nuclear receptor corepressors 1 or 2 (NCoR1 or 2) in the absence of its 
bound ligand. PPARγ transactivation activity is also reduced by phosphorylation at 
Ser112 of PPARγ2 by extracellular signal-regulated kinase (ERK), c-Jun N-terminal 
Kinase (JNK), or p38 MAPKs, and a phosphorylation-dependent sumoylation at K107 
[142]. In addition, a non-genomic role for PPARγ is emerging, as a number of PPARγ-
dependent processes are too rapid to involve transcriptional responses [143, 144]. The 
critical role of PPARγ in the response to t10c12 CLA is demonstrated by the attenuated 
responses that occur on addition of PPARγ agonists [109, 110].  
         SIRT1 is a NAD+-dependent histone/protein deacetylase that is involved in 
regulating cell energy metabolism, cell stress, and cell fate [145]. SIRT1 directly binds to 
NCoR1 and directly or indirectly to PPARγ to repress PPARγ transactivation activity, 
inhibit adipogenesis, and increase fat loss in adipocytes [146]. SIRT1 deacetylates liver 
kinase B1 (LKB1), facilitating the ability of LKB1 to phosphorylate AMPK, defining a 
SIRT1/LKB1/AMPK signaling pathway that provides one of the connections between 
SIRT1 and AMPK for regulating energy metabolism [147, 148]. SIRT1 also has an anti-
inflammatory effect due to its removal of acetyl groups from NF-κB, thereby inhibiting 
NF-κB transactivation activity [149]. SIRT1 activity can be influenced by exogenous 
chemicals. Sirtinol and nicotinamide inhibit SIRT1 and 2, and possibly other sirtuin 
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proteins [150]. Etomoxir inhibits fatty acid transport into mitochondria which prevents a 
rise in NAD+ levels that would facilitate SIRT1 activity [151], while SRT1720 
preferentially activates SIRT1 [152].  
        In this study, we analyzed the functional role of SIRT1 in the TG reduction that 
occurs in t10c12 CLA-treated 3T3-L1 adipocytes. Our objectives were to test whether 
SIRT1 was functionally required for robust triglyceride reduction, and whether SIRT1, 
AMPK, and PPARγ cross regulated each other in the response. These experiments were 
performed by using activators, inhibitors, or siRNA that affected these pathways and 
analyzing their effects on TG levels, fatty acid metabolism, and post-translational 
modifications or activity levels of SIRT1, AMPK, and PPARγ proteins. 
Experimental Procedures 
Reagents 
          Compound C was purchased from Calbiochem (San Diego, CA). Bovine serum 
albumin (BSA, > 99% fat free), dexamethasone, etomoxir, GW9662, insulin, isobutyl-1-
methylxanthine, metformin, nicotinamide, phenformin, and sirtinol were purchased from 
Sigma (St. Louis, MO). Ciglitazone, pioglitazone, rosiglitazone, SP600125, troglitazone, 
and U0126 were from Fisher (Pittsburgh, PA). SRT1720 was from Cayman Chemical 
(Ann Arbor, MI). T10c12 CLA (90%, #UC-61-A) was from Nu-Chek Prep, Inc (Elysian, 
MN). Antibodies to acetyl-NF-κB p65 (acetyl K310), p-PPARγ (phospho S112) and 
negative control siRNA were from Abcam (Austin, TX).  Protein A agarose beads, 
antibodies to β-actin, NCOR1, NF-κB p65, PPARγ, SIRT1, or anti-goat or anti-rabbit 
secondary antibodies coupled to horseradish peroxidase, and Sirt1 siRNA were purchased 
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from Santa Cruz Biotechnology (Santa Cruz, CA), while antibodies to p-AMPK, AMPK, 
p-ACC, and ACC were from Cell Signaling (Beverly, MA).   
3T3-L1 cell culture, differentiation, and chemicals  
          3T3-L1 fibroblasts [85] were cultured in Dulbecco's modified Eagle's medium 
(DMEM; Invitrogen, Carlsbad, CA) containing 10% bovine calf serum (Fisher, 
Pittsburgh, PA) and differentiated as described [111]. When present, chemicals were 
dissolved in DMSO, with the exception that 2 mmol/L metformin and 0.1 mmol/L 
phenformin were dissolved in water, and were added directly to the media at ≤ 0.2% of 
the final volume in the media at the following concentrations: 5 µmol/L ciglitazone, 10 
µmol/L compound C, 10 µmol/L etomoxir, 10 µmol/L GW9662, 10 µmol/L nicotinamide, 
5 µmol/L pioglitazone, 5 µmol/L rosiglitazone, 10 µmol/L sirtinol, 10 µmol/L SP600125, 
8 µmol/L SRT1720, 5 µmol/L troglitazone, or 10 µmol/L U0126, and were added 1 h 
before adding fatty acids. Fatty acids, either linoleic acid or trans-10, cis-12 CLA, were 
dissolved in 0.1 M KOH, diluted into fatty acid free (>99%) bovine serum albumin (BSA) 
in phosphate buffered saline at a 1:1 ratio (2 mmol/L BSA: 2 mmol/L fatty acid), pH 
adjusted to 7.4, and added to the cultures containing 5.5 to 6 d post-differentiated 3T3-L1 
adipocytes [111].  
Fatty acid biosynthesis, oxidation, and lipolysis assays 
           Fatty acid biosynthesis was measured in differentiated adipocytes after 24 h by 
removing the treatment media and incubating the adipocytes in Hanks’ Balanced Salt 
Solution (HBSS; Invitrogen, Carlsbad, CA) containing 37 KBq [14C]-acetate [specific 
activity 2.1 GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA) ] for 30 min 
(incorporation was linear for 60 min). Cells were washed in PBS three times, pelleted, 
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and then resuspended in 100 µl PBS and 0.1% SDS.  Lipids were extracted in 1 ml of 2:1 
chloroform:methanol [153] and measured by scintillation counting. Cells briefly exposed 
to 37 KBq [14C]-acetate, followed by immediate washing and extracted as above, were 
used to determine background levels, which were subtracted from sample values. Fatty 
acid oxidation was measured in differentiated adipocytes in 3.5 cm culture plates 12 h 
after starting treatments by adding 37 KBq [14C]-oleic acid [specific activity 1.7-2.2 
GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA) ] to the treatment media for 2 h 
and collecting [14C]-CO2 for 1 hr in collection jars as reported [138]. For lipolysis assays, 
the TG pool of differentiated adipocytes was labeled by adding 37 KBq [14C]-acetate 
[specific activity 1.5-2.2 GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA) ] to 
the media for 4 h, after which time the plates were washed four times with PBS, and 
specific experimental media treatments were initiated. Media (0.1 ml) was collected after 
24 h, lipids extracted in 1 ml of 2:1 chloroform:methanol [153] and measured by 
scintillation counting. The use of labeled [14C]-acetate and the 2:1 chloroform:methanol 
extraction step considerably reduced non-specific background to 50 DPM, as determined 
by using the above protocol on cells that had been briefly exposed to 37 KBq [14C]-
acetate in media.  
siRNA transfection 
         3T3-L1 adipocytes, 5 d post differentiation, were transfected by siQUEST 
transfection reagent (Mirus, Madison, WI), using final concentrations of 2 µl of siQUEST 
reagent per ml of media and siRNA at 40 nmol/L, 24 hours before adding fatty acids .  
Immunoblot analysis 
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           Nuclear and cytosolic extracts were isolated using a nuclear extract kit (Active 
Motif, Carlsbad, CA). Equal amounts of proteins were separated by SDS-PAGE, 
transferred to Immun-blot PVDF membrane (Bio-Rad Laboratories, Hercules, CA), 
probed with the indicated primary antibodies, and detected with secondary antibodies. 
Enhanced chemiluminescence (Pierce, Rockford, IL) was used for detection. Band 
intensities were determined from digital images from exposures in the linear range using 
software (Quantity One, Biorad, Hercules, CA). All western blot analyses were repeated 
at least three times. 
Immunoprecipitation 
           Immunoprecipitations were performed according to the procedure described [146]. 
In brief, the collected 3T3-L1 adipocytes were sonicated, lysates were centrifuged, and 
aliquots of the supernatants were immunoprecipitated overnight with specific antibody or 
control nonspecific IgG serum. Protein A agarose beads were used to bind the specific or 
non-specific antibody complexes, the protein A beads containing bound proteins were 
washed five times, and the bound proteins were eluted in SDS sample buffer for 
immunoblot analysis. 
Quantification of TG content 
           Cell isolation and TG measurements were performed according to the 
manufacturer’ instructions using TG reagent (T2449; Sigma, St. Louis, MO) and free 
glycerol reagent (F6428; Sigma, St. Louis, MO). TG data are expressed as nmol of TG 
per mg of protein.    
Measurement of MCP-1 and COX2 mRNA 
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          Total RNA was extracted by TRIzol (Invitrogen) following the manufacturer’s 
protocol. Total RNA (2 µg) was used for cDNA synthesis. Real-time PCR was performed 
by a Bio-Rad iCycler using iQ SYBR Green Supermix reagent (Bio-Rad, Hercules, CA) 
using PCR primers for MCP-1 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
[111], and COX2 [111]. MCP-1 and COX2 mRNA levels were normalized to GAPDH, 
which showed no significant variation in microarray analyses between linoleic acid and 
t10c12 CLA treatments. Experiments were repeated three times, and each sample was 
analyzed using one RNA control and two replicates of each cDNA pool, and the relative 
amounts of MCP-1, COX2 and GAPDH were calculated using the comparative CT 
method [88], according to the manufacturer’s software (Bio-Rad, Hercules, CA). Cycle 
numbers were used to calculate gene expression levels in the log linear amplification 
range.  
Statistical Analysis 
          One or two-way ANOVA was used to analyze the data. Pairwise comparisons were 
calculated using Tukey’s test and were considered significant for p≤0.05. All analyses 
were performed using SAS software (SAS, Cary, NC). 
 
Results  
 
         We first determined whether increased SIRT1 activity would lower TG levels in 
t10c12 CLA treated adipocytes. To specifically activate SIRT1, we used SRT1720, as 
this chemical is known to preferentially activate SIRT1 at 8 µM [152]. SRT1720, in 
combination with 50 µM t10c12 CLA, significantly lowered TG to 55% of the linoleic 
acid (LA) control levels, while 50 µM t10c12 CLA alone only lowered TG to 70% (Fig. 
1A; In our experiments, we used 50 µM t10c12 CLA if assaying chemicals that increased 
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TG loss, but otherwise used 100 µM t10c12 CLA in order to obtain large changes in TG 
levels or in the molecular responses of interest). In contrast, addition of 100 µM t10c12 
CLA in combination with a SIRT inhibitor, either sirtinol or nicotinamide, significantly 
increased TG levels to 67% and 68% of the LA control, respectively, relative to the 50% 
TG level caused by 100 µM t10c12 CLA treatment (Fig.1. B). Etomoxir, which inhibits 
SIRT activity indirectly by reducing NAD+ levels via inhibition of mitochondrial fatty 
acid transport and oxidation [151], was used in combination with t10c12 CLA, and 
significantly increased TG levels  to 72% of the LA control, relative to the 44% TG level 
in the t10c12 CLA treatment (Fig. 1C). These data indicated SIRT1 activity might be 
participating in the TG loss response caused by t10c12 CLA treatment.  
         SiRNA was used to reduce SIRT1 expression to confirm the functional involvement 
of SIRT1 in the response to t10c12 CLA. As a baseline for this comparison, we 
determined that treatment with t10c12 CLA did not change SIRT1 or β-actin protein 
levels (Fig. 1D). SiRNA treatment reduced SIRT1 protein levels by 53% but not affect β-
actin levels, while a control siRNA did not change SIRT1 or β-actin amounts (Fig. 1E). 
In the presence of LA, the siRNA SIRT1 treatment had TG levels that were not 
significantly different than those in the control siRNA treatment (Fig. 1F).  In contrast, in 
the presence of t10c12 CLA, the siRNA SIRT1 treatment had TG levels that were 72% of 
the LA control, while the control siRNA treatment had TG levels of 47% of the LA 
control (Fig. 1F). Taken together with the above inhibitor studies, these results suggested 
that inhibition of SIRT1 significantly interfered with the TG loss caused by t10c12 CLA.  
          The involvement of SIRT1 in t10c12 CLA-mediated changes in the rates of fatty 
acid biosynthesis, oxidation, and lipolysis as well as in the induction of two key 
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inflammatory mRNAs was then measured to gain insights into how SIRT1 affected these 
specific pathways. Adipocytes treated with t10c12 CLA had a 77% reduction in their rate 
of lipogenesis (Fig. 2A). The combination of t10c12 CLA and sirtinol significantly 
changed this to a 47% reduction in the rate of lipogenesis (Fig. 2A). This result indicated 
SIRT1 activity was involved in inhibiting the rate of fatty acid biosynthesis. Adipocytes 
treated with t10c12 CLA exported 61% more radioactively-labeled lipids than LA treated 
cells (Fig. 2B), but this t10c12 CLA-mediated lipolysis was not significantly affected by 
sirtinol (Fig. 2B). The rate of fatty acid oxidation was increased by 272% in t10c12 CLA-
treated adipocytes, but sirtinol did not significantly affect t10c12 CLA’s ability to 
increase this rate (Fig. 2C). The inflammatory MCP1 and COX2 mRNAs were highly 
induced by t10c12 CLA treatment (Fig. 2D-E). The SIRT1 activator SRT1720, in 
combination with t10c12 CLA, modestly attenuated the induction of MCP1 to 79% of 
t10c12 CLA levels, but did not significantly affect COX2 mRNA levels (Fig. 2D-E).  In 
contrast, the SIRT1 inhibitors, sirtinol or nicotinamide, when used in combination with 
t10c12 CLA, attenuated the induction of the mRNA of MCP1, to 65% or 58% of the 
t10c12 CLA control levels, respectively (Fig. 2D). Similarly, sirtinol or nicotinamide, 
when used in combination with t10c12 CLA, attenuated the induction of the mRNA of 
COX2, to 54% or 65% of the t10c12 CLA control levels, respectively (Fig. 2E). Taken 
together, these results indicated SIRT1 was involved with the inhibition of the rate of 
fatty acid biosynthesis and the increased induction of the inflammatory MCP1 and COX2 
mRNAs, but did not significantly affect lipolysis or fatty acid oxidation.   
          We next determined whether SIRT1 affected AMPK regulation during the response 
to t10c12 CLA. AMPK activity was measured by the amount of phosphorylation at 
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AMPK Thr172 (p-AMPK) and by the amount of phosphorylated ACC (p-ACC), one of 
AMPK’s key substrates in vivo. SIRT1 activator SRT1720 or SIRT inhibitors, with or 
without t10c12 CLA, had no significant effect on the amount of p-AMPK or p-ACC 
produced after 2 h of treatment (Fig. 3A).  However, when used in combination with 
t10c12 CLA for 12 h, SRT1720 significantly increased p-AMPK or p-ACC levels by 
37% or 43%, respectively, relative to the amounts present when treated by t10c12 CLA 
(Fig. 3B). Conversely, when used in combination with t10c12 CLA for 12 h, sirtinol or 
nicotinamide significantly attenuated p-AMPK levels to 66% or 83%, respectively, and 
p-ACC levels to 76% or 75%, respectively, relative to the amounts of these proteins in 
adipocytes treated with t10c12 CLA (Fig. 3B). Similarly, when used in combination with 
t10c12 CLA, siRNA targeting of SIRT1 significantly reduced p-AMPK to 54% and p-
ACC to 53% of their respective levels in the control treatment (Fig. 3C). Collectively, 
these results indicated SIRT1 increased AMPK activity levels at 12 h, but not within the 
first 2 h, after exposure to t10c12 CLA.  
         The involvement of PPARγ in the response to t10c12 CLA was then tested through 
addition of a PPARγ antagonist or agonist. The PPARγ antagonist GW9662 significantly 
reduced TG levels to 41%, relative to the LA control level, when used in combination 
with 50 µM t10c12 CLA, while 50 µM t10c12 CLA alone reduced TG levels to 70% (Fig. 
4A). Prior to examining the effects of a PPARγ agonist on the response to t10c12 CLA, 
we first determined the most potent PPARγ agonist amongst a set of four 
thiazolidinedione agonists, as measured by their ability to increase the amount of TG 
produced in differentiating adipocytes. Troglitazone was the most potent of the four 
agonists tested (Fig. 4B). Troglitazone significantly attenuated t10c12 CLA ‘s ability to 
   
80
reduce TG levels, as the combined treatment was not significantly different from the LA 
control (Fig. 4C). These results indicated that in adipocytes treated with t10c12 CLA, a 
PPARγ antagonist facilitates TG loss, while a PPARγ agonist interferes with TG loss.  
         The cross regulation between PPARγ and AMPK was next determined. When used 
in combination with t10c12 CLA for 12 h, PPARγ antagonist GW9662 increased AMPK 
and ACC phosphorylation levels by 33% and 34%, respectively (Fig. 4D). Conversely, 
when used in combination with t10c12 CLA for 12 h, troglitazone reduced AMPK and 
ACC phosphorylation levels by 45% and 39%, respectively (Fig. 4D). However, when 
used in combination with t10c12 CLA for 2 h there was no significant effect of these 
chemicals on AMPK or ACC phosphorylation levels (Fig. 4D). Therefore, although 
AMPK activation occurred at 2 h, cross regulation by PPARγ was not apparent at 2 h. 
Phosphorylation of PPARγ increased by 140% at 12 h, but not by 2 h, after t10c12 CLA 
treatment (Fig. 4E-F). When compound C was used in combination with t10c12 CLA, the 
amount of phosphorylated PPARγ was reduced by 41%, relative to the levels when 
treated by t10c12 CLA. This suggests AMPK activity was directly or indirectly involved 
in the phosphorylation of PPARγ (Fig. 4F). These results indicated AMPK and PPARγ 
cross regulated each other in the response to t10c12 CLA.  
         We next determined whether this cross regulation between AMPK and PPARγ 
occurred in the absence of t10c12 CLA. This was done by using two other chemicals to 
activate AMPK, alone or in combination with a PPARγ agonist or antagonist. Phenformin, 
a strong AMPK activator, reduced TG levels to 60% of those present in the untreated 
control adipocytes (Fig. 5A). When phenformin was used in combination with 
troglitazone, the amount of TG significantly increased to 86% of the amount in the 
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untreated control (Fig. 5A). Metformin, a weaker AMPK activator, only reduced TG 
levels to 87% of the amount present in the untreated control (Fig. 5B). The TG level was 
significantly reduced to 66% of the amount present in the untreated control when 
metformin was used in combination with the PPARγ antagonist GW9662 (Fig. 5B). 
These results demonstrated that the antagonistic cross regulation between AMPK and 
PPARγ that was observed in the response to t10c12 CLA also occurred in phenformin or 
metformin treated adipocytes in the absence of t10c12 CLA.    
        The regulation of SIRT1 activity by AMPK and PPARγ was then assessed. The 
deacetylation of the p65 subunit of NF-κB was used as a measure of SIRT1 activity in 
adipocytes [149]. The acetylation level of the p65 subunit of NF-κB was not significantly 
changed at 2 h (Fig. 6A), but was significantly reduced to 38% of control levels in 
adipocytes treated with t10c12 CLA for 12 h, suggesting SIRT1 deacetylation activity 
was increased. When t10c12 CLA was used in combination with sirtinol or nicotinamide, 
the amount of the acetylated p65 subunit of NF-κB increased to 84% or 60% of LA 
control levels, respectively (Fig. 6 B). These results supported the premise that SIRT1 
activity was involved in the deacetylation of the p65 subunit of NF-κB. The amount of 
the acetylated p65 subunit of NF-κB increased in a treatment using t10c12 CLA in 
combination with compound C to 80% of the LA control, relative to the 48% acetylation 
level produced by t10c12 CLA (Fig. 6C). This result indicated AMPK was directly or 
indirectly involved in regulating SIRT1 activity in the response to t10c12 CLA. 
Troglitazone was used to determine whether PPARγ affected SIRT1 activity levels. 
When used in combination with t10c12 CLA for 12 h, troglitazone-treated adipocytes 
significantly increased the amount of acetylated p65 subunit of NF-κB to 85% of LA 
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control levels (Fig. 6D). Conversely, adipocytes treated with t10c12 CLA and GW9662 
significantly reduced the amounts of acetylated p65 subunit of NF-κB to 40% of LA 
control levels. Collectively, these results indicated that AMPK and PPARγ positively and 
negatively regulated SIRT1 activity, respectively.  
         A possible mechanism for cross regulation of SIRT1 and PPARγ is through a direct 
protein interaction between SIRT1 and PPARγ [146]. Using a co-immunoprecipitation 
method, we observed that t10c12 CLA treatment resulted in a 138% increase in the 
amount of a SIRT1/PPARγ protein complex relative to the amount of this complex in the 
LA control, despite a 46% reduction in PPARγ protein levels in t10c12 CLA treated cells 
(Fig. 7). Again using a co-immunoprecipitation method, we observed that the amount of a 
protein complex containing SIRT1 and NCoR1 increased by 131% in the presence of 
t10c12 CLA (Fig. 7). These results demonstrated that there was increased binding of 
SIRT1 to PPARγ and NCoR1 in t10c12 CLA treated adipocytes.  
Discussion  
          Here we demonstrated that SIRT1 activity was involved in the TG loss response 
that occurred in t10c12 CLA-treated adipocytes. Inhibition of SIRT1 activity or 
abundance with sirtinol, nicotinamide, etomoxir [151], or siRNA attenuated the TG loss, 
while SIRT1 activation by SRT1720 increased the TG loss caused by t10c12 CLA. The 
100% difference in TG levels after 24 h of treatment with LA, relative to TG levels in 
t10c12 CLA-treated adipocytes, was caused by a combination of reduced fatty acid 
biosynthesis, increased lipolysis, and increased fatty acid oxidation in the t10c12 CLA-
treated adipocytes. The reduction in the rate of fatty acid synthesis was consistent with 
AMPK’s increased phosphorylation of ACC, thereby inhibiting its biosynthetic activity. 
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Fatty acid synthesis was also likely reduced by AMPK’s ability to phosphorylate and 
inhibit fatty acid synthase [80, 81]. Our finding that t10c12 CLA-treated adipocytes have 
increased lipolysis and fatty acid oxidation is consistent with a report that activated 
AMPK increases lipolysis after an initial delay [140], and that 3T3-L1 adipocytes treated 
with t10c12 CLA have increased rates of lipolysis and fatty acid oxidation [70]. Our 
studies indicated that SIRT1 activity participated in inhibiting fatty acid biosynthesis, but 
did not significantly affect lipolysis or fatty acid oxidation in the response to t10c12 CLA. 
In light of the cross regulation in the SIRT1/AMPK/ PPARγ axis, a possible explanation 
is that these pathways were coordinately regulated, but each pathway might have a 
different threshold for responding to this regulation.  For example, an increase in lipolysis 
or fatty acid oxidation might require less activation of AMPK, and therefore have less 
dependence on SIRT1 activity, than the inhibition of fatty acid biosynthesis.  
          Our molecular results indicated the response to t10c12 CLA included cross 
regulation between SIRT1, AMPK and PPARγ, as each protein affected the behavior of 
the others. Inhibitors or an activator of SIRT1 decreased or increased AMPK activity in 
t10c12 CLA-treated adipocytes, respectively. This is consistent with a 
SIRT1/LKB1/AMPK axis by which SIRT1 can affect AMPK activity [147, 148]. 
Treatment with t10c12 CLA caused more SIRT1 to bind to PPARγ and NCoRI, which 
reduces PPARγ activity [146], and which is consistent with the reduced transcription of 
lipogenic genes observed in t10c12 CLA treated adipocytes [12, 50, 67]. Inhibition of 
AMPK reduced SIRT1 activity as measured by the deacetylation of NF-κB, possibly by a 
mechanism in which AMPK-mediated changes in fatty acid oxidation affect the 
NAD+/NADH ratio that affects SIRT1 activity [151]. AMPK was directly or indirectly 
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responsible for the increased phosphorylated at Ser112 of PPARγ in t10c12 CLA treated 
adipocytes [109], as this effect was attenuated by compound C. Phosphorylation of 
PPARγ at Ser112 facilitates its SUMOylation at K107, and thereby decreasing its 
transactivation activity [142]. Agonists or antagonists of PPARγ caused reductions or 
increases in the activity of AMPK and SIRT1, respectively, demonstrating the repressive 
effect PPARγ has on the activities of these proteins. Importantly, the total amounts of 
AMPK and SIRT1 proteins did not change in the response to t10c12 CLA, suggesting 
that PPARγ did not alter the amounts of these proteins through a transcriptional 
mechanism. As such, our results support an emerging role for PPARγ in regulating non-
genomic processes [143, 144].  
          An inflammatory response has been demonstrated to be an important component of 
the TG reduction in t10c12 CLA treated adipocytes [60, 111]. Deacetylation of NF-κB by 
SIRT1 is expected to reduce NF-κB’s transcriptional induction of pro-inflammatory 
genes [154]. In possible support of this, resveratrol, a SIRT1 activator, inhibits the 
inflammatory and cellular stress response caused by t10c12 CLA treatment [110].  
However, resveratrol is also an agonist of PPARγ, which opposes the molecular 
responses to t10c12 CLA [109], making it more difficult to interpret the effects of 
resveratrol. We found that the functional consequence of inhibiting SIRT1 activity was 
an attenuation of the inflammatory response in t10c12 CLA-treated adipocytes. This 
result is consistent with SIRT1’s ability to activate AMPK, possibly via SIRT1’s ability 
to increase the activity of LKB1, an upstream kinase that phosphorylates AMPK [147, 
148]. AMPK is critical for the t10c12 CLA-mediated inflammatory response in 
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adipocytes as demonstrated by the reduction in this response when AMPK is inhibited by 
compound C [111].   
          Our experiments using AMPK activators other than t10c12 CLA to manipulate 
these pathways gave results consistent with those obtained with t10c12 CLA. Phenformin, 
a potent AMPK activator, caused a TG loss similar to that caused by t10c12 CLA 
treatment. Troglitazone, the most potent PPARγ agonist in our 3T3-L1 adipocyte system, 
attenuated the TG loss caused by phenformin. Troglitazone reduced the amount of 
phosphorylated AMPK and ACC caused by t10c12 CLA treatment, providing a likely 
explanation for how it inhibits the TG loss caused by phenformin. A PPARγ antagonist 
increased the amount of TG loss when used with metformin, a moderate AMPK activator. 
This latter finding supports a hypothesis that both AMPK activation [111] and reduced 
PPARγ activity [60] are important for reducing TG levels in the response to t10c12 CLA. 
We interpret these results to mean that the ability of these proteins to cross regulate each 
other allows this endpoint to be achieved by either strong activation of AMPK (by t10c12 
CLA or phenformin) or by a combination of a moderate AMPK activator (metformin) 
and a PPARγ antagonist.  
          Both AMPK and SIRT1 play major roles in regulating cellular energy homeostasis 
and in response to caloric restriction [155, 156]. The involvement of AMPK and SIRT1 
in the molecular response to t10c12 CLA is consistent with an overall similarity to the 
response to cellular energy restriction. This is supported by the strong similarity of the 
whole genome transcriptional response of adipocytes treated with t10c12 CLA to the 
response to metformin [111], which affects the cellular AMP/ATP ratio [128, 129], and 
by the ability of phenformin to cause TG losses similar to those caused by t10c12 CLA. 
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Our results support a non-genomic role for PPARγ [143, 144] in its cross regulation of 
SIRT1 and AMPK activities. This cross regulation occurred in a later stage of the 
response after the initial activation of AMPK, consistent with the suggestion that AMPK  
activation is a critical early event [111]. The signaling pathways used by t10c12 CLA to 
activate AMPK remain unknown. 
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Figures 
 
 
 
Figure 1.  SIRT activity affects TG levels in t10c12 CLA treated 3T3-L1 adipocytes. a-c 
Triglyceride (TG) levels were measured in differentiated adipocytes after incubation with 
LA (-) or t10c12 CLA (+), with or without SRT1720 (SRT), sirtinol (SOL), nicotinamide 
(NAM), or etomoxir (ETO) for 24 h. d Western blot analysis of the amount of SIRT1 and 
β-actin proteins at 2 or 12 h, or in e, after treatment with siRNA against SIRT1 or with 
control siRNA after 12 h. f Triglyceride (TG) amounts 24 h after treatments as in e. Each 
bar in panels a-f represents the mean + SEM (n=3), and is representative of three 
independent experiments (a-c, and f) or is the mean of three independent experiments (d-
e). Means not sharing a common letter differ, P ≤  0.05.  
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Figure 2. SIRT1 affects fatty acid metabolism and inflammatory mRNA levels. a-c The 
effects of 100 µmol/L of t10c12 CLA, with or without sirtinol (SOL), on fatty acid 
biosynthesis, lipolysis, or fatty acid oxidation were measured by incorporation of  [1-
14C]-acetate (a) or release of labeled lipids (b) or CO2 (c) derived from  [1-14C]-acetate or 
[1-14C]-oleate, respectively (disintegrations per minute: dpm). d-e RNA levels were 
analyzed for MCP-1 and COX2 relative to GAPDH by reverse transcription and 
quantitative PCR. The relative amounts of MCP-1 and COX2 mRNA are shown as bar 
graphs.  Each bar in panels a-e represents the mean + SEM (n=3 for a-b or n=2 for c-e), 
and is representative of three independent experiments.  Means not sharing a common 
letter differ, P ≤  0.05. 
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Figure 3.  SIRT1 activity affects ACC and AMPK phosphorylation levels after t10c12 
CLA treatment. Differentiated 3T3-L1 adipocytes were incubated with 100 µmol/L LA (-) 
or t10c12 CLA (+): a with or without SRT1720 (SRT), sirtinol (SOL), or nicotinamide 
(NAM) for 2 or b 12 h; or c with siRNA to SIRT1 (siSIRT1) or control siRNA (siCON). 
Representative western blots indicate the proteins detected with antibodies to p-ACC (p-
Ser 79), or total ACC, p-AMPK (p-Thr 172), or total AMPK. Each bar represents the 
mean + SEM of the ratio of the phosphorylated to total form of each protein 
(phospho/total), n=3 independent experiments. Means for p-AMPK/AMPK (a-e) or p-
ACC/ACC (u-x) not sharing a common letter differ, P ≤  0.05.  
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Figure 4.  PPARγ antagonists and agonists affect TG levels and modulate p-AMPK 
activity levels in t10c12 CLA treated 3T3-L1 adipocytes. a Differentiated adipocytes 
were incubated with 50 µmol/L LA (-) or t10c12 CLA (+) with or without GW9662 
(9662) for 24 h and TG levels were measured.  b Differentiating adipocytes were treated 
with either control media (0), troglitazone (Tro), ciglitazone (C), rosiglitazone (R), or 
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pioglitazone (P) to determine which PPARγ agonist was most effective for increasing TG 
levels. c Differentiated 3T3-L1 adipocytes were incubated with 100 µmol/L LA or t10c12 
CLA, with or without troglitazone (Tro), and TG levels were measured after 24 h. d 
Adipocytes were treated as in a or c for 2 or 12 h using 100 µmol/L LA (-) or t10c12 
CLA (+), and representative western blots indicate the proteins detected with antibodies 
to p-ACC (p-Ser 79), total ACC. p-AMPK (p-Thr 172), or total AMPK. The ratio of the 
phosphorylated to total form of each protein (phospho/total) is shown in the bar graphs. 
e-f The amount of phosphorylated or total PPARγ was measured after 2 or 12 h of 
treatment with 100 µmol/L LA (-) or t10c12 CLA (+), and with or without compound C 
(Comp.C) at 12 h. The ratio of the amount of phosphorylated to total PPARγ is shown in 
the bar graphs. Each bar in panels a-f represents the mean + SEM (n=3), and is 
representative of three independent experiments (a-c) or is the mean of three independent 
experiments (d-f). Means within each data type (a-e or u-x) not sharing a common letter 
differ, P ≤  0.05. 
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Figure 5.  PPARγ agonists or antagonists affect the TG loss caused by AMPK activators.  
a Differentiated 3T3-L1 adipocytes were incubated with or without 0.1 mmol/L 
phenformin (Phen), with or without troglitazone (Tro), and TG levels were measured 
after 24 h. b TG levels were measured in differentiated 3T3-L1 adipocytes in media 
lacking or containing 2 mmol/L metformin (Met), with or without GW9662 (9662) for 24 
h. Each bar represents the mean + SEM (n=3), and is representative of three independent 
experiments. Means not sharing a common letter differ, P ≤  0.05.  
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Figure 6.  SIRT1, AMPK and PPARγ affect the t10c12 CLA-dependent decrease in the 
amount of acetylated NF-κB. The amount of acetylation on the p65 subunit of NF-κB, or 
the total amount of p65, was enriched by immunoprecipitation of p65, and detected by 
immunoblot analysis of the immunoprecipitated proteins with antibodies to detect either 
acetylated p65 or total p65. The ratio of the acetylated to total p65 is shown (Acetyl-
p65/p65). a-c Differentiated 3T3-L1 adipocytes were incubated with 100 µmol/L LA (-) 
or t10c12 CLA (+) a for 2 h, or b for 12 h, with or without sirtinol (SOL) or nicotinamide 
(NAM), or c with or without compound C (Comp.C).  d The effects of troglitazone (Tro) 
or GW9662 (9662), in combination with LA (-) or t10c12 CLA (+), on the acetylation of 
the p65 subunit of NF-κB was measured. Each bar in panels a-d represents the mean + 
SEM (n=3) of three independent experiments.  Means not sharing a common letter differ, 
P ≤  0.05. 
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Figure 7.  Treatment with t10c12 CLA increases the interaction of SIRT1 with PPARγ or 
NCoR1. Differentiated 3T3-L1 adipocytes were incubated with 100 µmol/L LA (-) or 
t10c12 CLA (+) for 12 h, and a portion of the extracts were immunoprecipitated with 
antibody to SIRT1. Representative western blots indicate the proteins detected from the 
crude extracts (5% input) or when the immunoprecipitated (IP) proteins were probed with 
antibodies to SIRT1, PPARγ, or NCoR1. Each bar represents the mean + SEM (n=3) of 
three independent experiments. Means within each data type not sharing a common letter 
differ, P ≤  0.05. 
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Chapter V. PPARδ and AMPK antagonize PPARγ to cause triglyceride loss in 
conjugated linoleic acid treated adipocytes 
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Introduction 
 
          Conjugated linoleic acid (CLA) reduces adiposity in mouse and human adipocytes, 
and trans-10, cis-12 CLA (t10c12 CLA) is an active isomer capable of causing this 
response [16, 24, 60, 69, 137]. Treatment of 3T3-L1 adipocytes with t10c12 CLA 
increases the rates of lipolysis and fatty acid oxidation [70], and reduces the rate of fatty 
acid biosynthesis [157]. The molecular responses to t10c12 CLA  are highly dependent 
on the activity status of AMP-activated protein kinase (AMPK) [158], peroxisome 
proliferator-activated receptor (PPAR)γ protein [60], and an inflammatory response [60, 
158].  
          AMPK is a central regulator of cellular energy levels that is activated by increases 
in the cellular AMP/ATP ratio, various cellular stresses [80, 81], AICAR 
(aminoimidazole carboxamide ribonucleotide), or treatment of adipocytes [158] or mice 
[139] with t10c12 CLA or mixed isomers of CLA. Activated AMPK is required for the 
TG reduction that occurs in t10c12 CLA treated adipocytes [158], and AMPK activation 
requires phosphorylation at Thr172 [135]. Two of the proteins phosphorylated and 
thereby inhibited by activated AMPK are acetyl CoA carboxylase and fatty acid synthase, 
two rate-limiting lipid biosynthetic enzymes. Through this and other mechanisms [80, 81], 
activated AMPK decreases lipogenesis, increases fatty acid oxidation, and increases 
lipolysis in adipocytes in vitro [157] and in vivo after an initial delay [140].  
          PPARγ and PPARδ are nuclear receptor transcription factors that can be activated 
by fatty acids and other ligands in adipocytes. PPARγ regulates lipogenesis and is a key 
regulatory point for controlling inflammation in adipocytes [115]. PPARδ is a 
ubiquitously expressed and regulates fatty acid oxidation, and mitochondrial abundance, 
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primarily in muscles, but a role in WAT is emerging [159-163]. PPARγ plays a critical 
role in the response to t10c12 CLA, as the response is attenuated on addition of PPARγ 
agonists [109, 110, 157], and enhanced TG loss occurs on addition of a PPARγ 
antagonist [157, 164]. PPARγ has increased phosphorylation [109] and reduced protein 
levels in t10c12 CLA treated adipocytes [60, 158]. Reduced levels of PPARδ expression 
caused increased TG accumulation in 3T3-L1 adipocytes, indicating a role for PPARδ in 
opposing lipid accumulation [165]. Retinoid X receptor (RXR) is a heterodimeric partner 
for many nuclear receptors, including PPARγ and PPARδ. Competition between nuclear 
receptors for limiting amounts of RXR is observed in some systems [166]. PPARδ also 
physically interacts with AMPK, and constitutively activated PPARδ results in activated 
AMPK in muscle cells, indicating possible cross regulation occurs between these proteins 
[163]. These aspects of PPARδ biology suggested it could be involved in the TG loss 
response in t10c12 CLA treated adipocytes.  
          Here we used chemical activators, inhibitors, or siRNA to affect PPARδ, and 
measured the effects of these treatments on TG levels, fatty acid biosynthesis, lipolysis, 
and oxidation, as well as on protein interactions in 3T3-L1 adipocytes, and on the ability 
of t10c12 CLA and GW0742 to reduce body and adipose tissue mass in mice. Our 
objectives were to test whether PPARδ was functionally involved in the TG reduction 
response to t10c12 CLA, and whether this response affected the protein interactions of 
PPARγ and PPARδ with RXR, and of PPARδ with AMPK.  
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Methods 
Reagents 
         Bovine serum albumin (BSA, > 99% fat free), dexamethasone, GW0742, GSK0660, 
insulin, and isobutyl-1-methylxanthine, were purchased from Sigma (St. Louis, MO). 
T10c12 CLA (90%, #UC-61-A) was from Nu-Chek Prep, Inc (Elysian, MN). Negative 
control siRNA was from Abcam (Austin, TX).  Protein A agarose beads, antibodies to β-
actin, PPARδ, and PPARγ, anti-rabbit and anti-goat secondary antibodies coupled to 
horseradish peroxidase, and siRNA were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA), while antibodies to p-AMPK, AMPK were from Cell Signaling 
(Beverly, MA).   
Animals 
         C57Bl/6J male mice were housed individually at 22 °C with 12 h light and 12 h 
dark. All mice were fed AIN-93G diet ([84]; Dyets, Inc., Bethlehem, PA) for 5 d before 
beginning the treatments. Mice were blocked by initial body weight and assigned to one 
of the four treatment diets.  Specific diets contained either 70 g/kg soy oil without t10c12 
CLA or 68 g/kg soy oil with 2 g/kg t10c12 CLA. GW0742, when present, was 
incorporated in the diet at 7 mg/kg. Diet was changed twice each week, and mice were 
allowed to eat ad libitum. After 14 d of these treatments, body weight was measured and 
mice were killed in the fed state between 09:00 and 13:00 h by carbon dioxide asphyxia.  
Retroperitoneal and epididymal fat pads were harvested and weighed. All procedures 
were approved by the University of Nebraska Institutional Animal Care and Use 
Committee. 
3T3-L1 cell culture, differentiation, and chemicals  
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          3T3-L1 fibroblasts [85] were cultured in Dulbecco's modified Eagle's medium 
(DMEM; Invitrogen, Carlsbad, CA) containing 10% bovine calf serum (Fisher, 
Pittsburgh, PA) and differentiated as described [158]. When present, chemicals were 
dissolved in DMSO, and were added directly to the media at ≤ 0.2% of the final volume 
in the media at the following concentrations: 9 µmol/L GW0742, or 5 µmol/L GSK0660, 
and were added 1 h before adding fatty acids. Fatty acids, either linoleic acid or t10c12 
CLA, were dissolved in 0.1 M KOH, diluted into fatty acid free (>99%) bovine serum 
albumin (BSA) in phosphate buffered saline at a 1:1 ratio (2 mmol/L BSA: 2 mmol/L 
fatty acid), pH adjusted to 7.4, and added to the cultures containing 5.5 to 6 d post-
differentiated 3T3-L1 adipocytes [158].  
Fatty acid biosynthesis, oxidation, and lipolysis assays  
         Fatty acid biosynthesis was measured in differentiated adipocytes 24 h after starting 
treatments by removing the treatment media and incubating the adipocytes in Hanks’ 
Balanced Salt Solution (HBSS; Invitrogen, Carlsbad, CA) containing 37 KBq [14C]-
acetate [specific activity 2.1 GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA) ] 
for 30 min (incorporation was linear for 60 min, data not shown). Cells were washed in 
PBS three times, pelleted, and then resuspended in 100 µl PBS and 0.1% SDS.  Neutral 
lipids were extracted in 1 ml of 2:1 chloroform:methanol [153] and measured by 
scintillation counting. Cells briefly exposed to 37 KBq [14C]-acetate in media, followed 
by immediate washing and extraction as above, were used to determine background 
levels, which were subtracted from sample values.  
          Fatty acid oxidation was measured in differentiated adipocytes in 3.5 cm culture 
plates 12 h after starting treatments by adding 37 KBq [14C]-oleic acid [specific activity 
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2.2 GBg/mmol, (PerkinElmer Radioisotopes, Waltham, MA) ] to the treatment media for 
2 h and then collecting [14C]-CO2 for 1 hr in collection jars as reported [138].  
         For lipolysis assays, the TG pool of differentiated adipocytes was labeled by adding 
37 KBq [14C]-acetate [specific activity 2.1 GBg/mmol, (PerkinElmer Radioisotopes, 
Waltham, MA) ] to the media for 4 h, after which time the plates were washed four times 
with PBS, and specific experimental media treatments were initiated. Media (0.1 ml) was 
collected after 12 h, neutral lipids extracted in 1 ml of 2:1 chloroform:methanol [153] and 
measured by scintillation counting. The use of labeled [14C]-acetate and the 2:1 
chloroform:methanol extraction step considerably reduced non-specific background to 50 
dpm, as determined by using the above protocol on cells that had been briefly exposed to 
37 KBq [14C]-acetate in media.  
siRNA transfection 
            3T3-L1 adipocytes, 5 d post differentiation, were transfected by siQUEST 
transfection reagent (Mirus, Madison, WI), using final concentrations of 2 µl of siQUEST 
reagent per ml of media and siRNA at 40 nmol/L, 24 hours before adding fatty acids .  
Immunoblot analysis 
           Nuclear and cytosolic extracts were isolated using a nuclear extract kit (Active 
Motif, Carlsbad, CA). Equal amounts of proteins were separated by SDS-PAGE, 
transferred to Immun-blot PVDF membrane (Bio-Rad Laboratories, Hercules, CA), 
probed with the indicated primary antibodies, and detected with secondary antibodies. 
Enhanced chemiluminescence (Pierce, Rockford, IL) was used for detection. Band 
intensities were determined from digital images from exposures in the linear range using 
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software (Quantity One, Biorad, Hercules, CA). All western blot analyses were repeated 
at least three times. 
Immunoprecipitation 
           Immunoprecipitations were performed according to the procedure described [146]. 
In brief, the collected 3T3-L1 adipocytes were sonicated, lysates were centrifuged, and 
aliquots of the supernatants were immunoprecipitated overnight with specific antibody or 
control nonspecific IgG serum. Protein A agarose beads were used to bind the specific or 
non-specific antibody complexes, washed five times, and the bound proteins were eluted 
in SDS sample buffer for immunoblot analysis. 
Quantification of TG content.  
          Cell isolation and TG measurements were performed according to the 
manufacturer’ instructions using TG reagent (T2449; Sigma, St. Louis, MO) and free 
glycerol reagent (F6428; Sigma, St. Louis, MO). TG data are expressed as nmol of TG 
per mg of protein.    
Measurement of mRNA levels.  
         Total RNA was extracted by TRIzol (Invitrogen) following the manufacturer’s 
protocol. Total RNA (2 µg) was used for cDNA synthesis. Real-time PCR was performed 
by a Bio-Rad iCycler using iQ SYBR Green Supermix reagent (Bio-Rad, Hercules, CA) 
using PCR primers for MCP1 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
[158], ANGPTL4 [167], CPT1a [168], and PDK4 [169]. Target mRNA levels were 
normalized to GAPDH, which showed no significant variation in microarray analyses 
between linoleic acid and t10c12 CLA treatments. Experiments were repeated three times, 
and each sample was analyzed using one RNA control and two replicates of each cDNA 
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pool, and the relative amounts of each target mRNA and GAPDH were calculated using 
the comparative CT method [88], according to the manufacturer’s software (Bio-Rad, 
Hercules, CA). Cycle numbers were used to calculate gene expression levels in the log 
linear amplification range.  
Statistical Analysis 
         Two-way ANOVA was used to analyze the data as follows: for Figures 1, 2b, 3, 4a, 
5 and Table 1, the main effects of CLA (LA or CLA) and GW0742 (- or +) or GSK0660 
(- or +), and their interaction (CLA x GW0742 or CLA x GSK0660) were analyzed. One-
way ANOVA was used to analyze the data in Figures 2a, and 4b. Pairwise comparisons 
were calculated using Tukey’s test (criterion for significance, α ≤ 0.05, except for Table 1 
for which α ≤ 0.1 was used).  All analyses were performed using JMP8 software (SAS, 
Cary, NC). 
Results 
           The possible involvement of PPARδ in the response to t10c12 CLA was first 
tested using an agonist or antagonist of PPARδ. Treatment with GW0742, an agonist, 
produced TG levels that were not significantly different at 86% of the LA control, but the 
combination of GW0742 and 50 µM t10c12 CLA had significantly lower TG levels at 
46% of the LA control (Fig. 1A; We generally used 50 µM t10c12 CLA if assaying 
chemicals that increased TG loss, but otherwise used 100 µM t10c12 CLA to obtain large 
changes in the molecular responses of interest). GSK0660, a PPARδ antagonist, had no 
significant effect on TG levels when used alone (101% of LA control), but significantly 
interfered with the ability of 100 µM t10c12 CLA to reduce TG levels at 72% of LA 
control as compared to a 50% level for 100 µM t10c12 CLA alone (Fig 1B). The effects 
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of the combination treatments of t10c12 CLA with PPARδ siRNA or random siRNA 
were significantly different, with TG levels of 77% or 55%, respectively, relative to the 
control treatment of LA and random siRNA (Fig 1 C). PPARδ protein levels were 
reduced by 47% by the treatment with siRNA against PPARδ relative to samples treated 
with a control random siRNA (Fig 1D). This siRNA-mediated attenuation of TG loss was 
consistent with the PPARδ antagonist result above, and collectively these results 
indicated that PPARδ facilitated TG loss in the response to t10c12 CLA. We next 
determined whether three PPARδ regulated genes [angiopoietin-related protein 4 
(ANGPTL4); carnitine palmitoyltransferase Ia (CPT1a); and pyruvate dehydrogenase 
kinase 4 (PDK4)] had increased mRNA levels, as an indicator of increased PPARδ 
transcriptional activity [170]. Their mRNA levels were significantly increased in t10c12 
CLA treated adipocytes by 108%, 78%, or 111% for ANGPTL4, CPT1a, or PDK4, 
respectively (Fig. 2 A). Taken together, these results indicated PPARδ was activated and 
facilitated TG loss in the response to t10c12 CLA.  
          We next determined the effects of PPARδ on specific pathways involved in the 
response to t10c12 CLA. We measured the effect of GW0742 and GSK0660 on the 
t10c12 CLA-dependent induction of monocyte chemotactic protein-1 (MCP1), an 
inflammatory mRNA induced by t10c12 CLA [158]. Treatment with t10c12 CLA and 
GW0742 did not significantly change MCP1 mRNA levels (Fig. 2B). However, treatment 
with t10c12 CLA and GSK0660 significantly reduced MCP1 mRNA levels to 32% of the 
t10c12 CLA control value (Fig. 2B). The effect of PPARδ on fatty acid biosynthesis, 
lipolysis, or oxidation was determined using t10c12 CLA and GSK0660. Fatty acid 
biosynthesis in adipocytes treated with t10c12 CLA alone was 45% of the LA control, 
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while the combination of t10c12 CLA and GSK0660 was moderately but significantly 
higher at 55% of the LA control value (Fig 3a). Fatty acid lipolysis with t10c12 CLA 
alone or in combination with GSK0660 was 159% and 99% of LA control levels, 
respectively (Fig 3b). Fatty acid oxidation with t10c12 CLA alone or in combination with 
GSK0660 was 311% and 128% of LA control levels, respectively (Fig 3c). These results 
indicated that PPARδ significantly attenuated the inflammatory pathway, as well as fatty 
acid lipolysis and oxidation, but only moderately affected inhibition of fatty acid 
biosynthesis in t10c12 CLA treated adipocytes.  
           Activated AMPK plays an essential role in the response to t10c12 CLA [158]. 
Therefore, the ability of PPARδ to affect AMPK activity was measured with t10c12 CLA 
alone or in combination with GW0742 or GSK0660. The amount of activated AMPK 
increased in the presence of t10c12 CLA, and this amount was further increased by 13% 
in combination with GW0742, or decreased by 46% in combination with GSK0660 (Fig 
4A). A possible mechanism for this effect was via a physical interaction between AMPK 
and PPARδ [163], and we hypothesized this interaction might be affected by t10c12 CLA 
treatment. We measured this interaction using a coimmunoprecipitation assay and 
determined that the amount of AMPK bound to PPARδ increased by 84% in t10c12 CLA 
treated adipocytes (Fig 4B). These results indicated a PPARδ agonist or antagonist 
affected AMPK activity, and that t10c12 CLA treated adipocytes had an increased 
amount of PPARδ bound to AMPK.  
           PPARγ protein levels are reduced in t10c12 CLA treated adipocytes [60, 158], and 
we tested whether activated PPARδ could compete more effectively with PPARγ for 
RXR. Therefore, the amount of PPARδ or PPARγ present in a protein complex with 
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RXR was measured by coimmunoprecipitation with RXR. The amount of PPARγ bound 
to RXR was significantly reduced to 32% of control LA levels in the presence of t10c12 
CLA, and this amount was further reduced to 20% when both t10c12 CLA and GW0742 
were present (Fig 5). The amount of PPARδ bound to RXR significantly increased by 
105% in t10c12 CLA treatments, and this amount increased further by 215% when both 
t10c12 CLA and GW0742 were present (Fig 5). These results indicated PPARδ competed 
more effectively for RXR in the presence of t10c12 CLA.  
           The above results suggested the combination of GW0742 and t10c12 CLA should 
be tested in mice for its ability to reduce body and WAT weight. Mice were fed diet with 
or without t10c12 CLA, and with or without GW0742. After two weeks body weight, 
retroperitoneal, and epididymal fat pads were measured (Table 1). The reductions in body 
weight were significant for t10c12 CLA (p=0.02) and GW0742 (p =0.08). The effects on 
retroperitoneal mass were significant for t10c12 CLA (p <0.01) and approached 
significance for GW0742 (p =0.14). The effects on epididymal mass were significant for 
t10c12 CLA (p <0.01) and GW0742 (p =0.06). None of the interactions between 
GW0742 and t10c12 CLA were significant (Table 1).  
Discussion 
 
         Here we demonstrated PPARδ played a positive role in reducing TG levels in 
t10c12 CLA treated adipocytes. In support of increased PPARδ activity, three PPARδ 
target genes showed increased mRNA levels in the response to t10c12 CLA. Inhibiting 
PPARδ protein activity or amounts with an antagonist or siRNA, respectively, attenuated 
the TG loss response caused by t10c12 CLA, while addition of a PPARδ agonist 
increased the TG loss. Functional analyses of PPARδ in several systems support its 
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involvement in TG loss [160, 163]. Overexpressed PPARδ decreased TG levels, and 
reduced levels of PPARδ increased TG levels, in 3T3-L1 adipocytes [165]. PPARδ was 
required for fatty acid transport and oxidation in human adipocytes [171].  Mice 
expressing constitutively active PPARδ had increased expression of genes involved with 
fatty acid oxidation and uncoupling protein 1 (UCP1), and had reduced adiposity [160]. 
PPARδ and AMPK are both required for efficient fatty acid oxidation in muscle cells 
[171]. Our results were in agreement with these studies, as PPARδ strongly affected 
t10c12 CLA’s ability to increase fatty acid oxidation and lipolysis, but only moderately 
affected the reduced rate of fatty acid biosynthesis in t10c12 CLA treated adipocytes.  
           PPARδ had increased binding to AMPK in t10c12 CLA treated adipocytes, 
consistent with the ability of AMPK to bind to PPARδ in muscle cells [163]. A PPARδ 
agonist or antagonist affected AMPK activity, as treatment with GW0742, an agonist of 
PPARδ, increased the amount of activated AMPK, while treatment with GSK0660, a 
PPARδ antagonist, reduced the amount of activated AMPK. The physical interaction of 
PPARδ and AMPK might be a mechanism by which PPARδ activity increased AMPK 
activity as constitutively-activated PPARδ resulted in activated AMPK in transgenic mice 
[163], and the PPARδ agonist GW501516 activated AMPK in muscle cells [171]. The 
ability of PPARδ to affect AMPK activity might explain observations that fatty acids 
activate AMPK [172, 173], as fatty acids are natural agonists of PPARδ [174].  As a fatty 
acid, t10c12 CLA is a potential ligand for PPARδ, but our data did not resolve whether it 
activated AMPK through direct binding to PPARδ or via an unknown indirect 
mechanism. Although the detailed mechanism by which PPARδ activates AMPK is 
unproven, it is clear that PPARδ’s ability to affect AMPK activity was predominantly 
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mediated by a non-transcriptional mechanism as total AMPK protein levels were not 
significantly changed. Non-genomic regulation of proteins involved in non-
transcriptional processes such as metabolic regulation is an emerging trend for the family 
of PPAR transcription factors, as similar behavior has been observed for PPARγ [143, 
157].   
         Activated AMPK results in reduced amounts of PPARγ protein [60, 158] and 
increased PPARγ phosphorylation [157], which reduces its transactivation activity [142]. 
Therefore, PPARδ’s ability to activate AMPK indirectly facilitated reduced amounts of 
PPARγ activity in the response to t10c12 CLA. Reduced amounts of PPARγ activity are 
important for t10c12 CLA-mediated TG loss, as activated PPARγ opposes t10c12 CLA 
effects [110, 157]. In addition to these indirect effects on PPARγ activity via changes in 
AMPK activity, PPARδ also reduced PPARγ activity via direct competition for RXR, the 
required heterodimeric partner for PPARγ and PPARδ [166, 175, 176]. The amount of 
the PPARγ/RXR heterodimeric protein complex decreased, and the amount of 
PPARδ/RXR increased, in the presence of t10c12 CLA. The amount of PPARγ/RXR 
heterodimeric protein complex was reduced further when both t10c12 CLA and GW0742 
were present, providing additional support for the ability of activated PPARδ to compete 
for RXR. Thus, PPARγ activity was reduced by a combination of AMPK-mediated and 
PPARδ-mediated mechanisms. Additionally, t10c12 CLA treatment increases the amount 
of Sirtuin 1 (SIRT1) bound to PPARγ [157], which represses PPARγ transactivation 
activity [146]. The inflammatory response is an important component of the TG loss 
caused by t10c12 CLA [60, 158], and both PPARγ and PPARδ are considered to have 
anti-inflammatory roles in many cell types [177]. However, we observed that inhibition 
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of PPARδ reduced the inflammatory response in t10c12 CLA treated adipocytes. This 
was consistent with PPARδ’s activation of AMPK, as activated AMPK is required for the 
inflammatory response to t10c12 CLA [158]. The combined effects of AMPK, PPARδ, 
and SIRT1 on reducing PPARγ activity facilitates an inflammatory response, as PPARγ 
plays an anti-inflammatory role in adipocytes [115].  
        The effects of t10c12 CLA and GW0742 in mice were promising as this 
combination produced the smallest average fad pads and the most reduction in the 
average body mass.  The effects of t10c12 CLA and GW0742 were significant for 
decreases in body mass and epididymal fat pads, and approached significance for 
retroperitoneal fat pads, but indicated trials with larger numbers of animals are needed to 
obtain more significant data. In support of our results, concurrent administration of the 
AMPK activator AICAR and a PPARδ agonist was more effective than a PPARδ agonist 
alone for increased running endurance in muscle tissue and reduced epididymal tissue 
mass in mice [163]. Our results indicate combinations of t10c12 CLA and a PPARδ 
agonist have potential for reducing adiposity in mammals. 
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Tables and figures 
 
Table 1.  The effect of GW0742 and t10c12 CLA on body weight or adipose tissue 
weight in mice1 
 
 
 
1 Data are presented as mean ± SEM, n = 11 for BW and RP, n=22 for EPI. Means in a 
row not sharing a common superscript differ, P < 0.1.  
2  C57Bl/6J male mice were fed 0.2% t10c12 CLA with or without GW0742 for two 
weeks.  
3 The changes in body weight (BW) or the final weights of the epididymal (EPI) or 
retroperitoneal (RP) were measured after 14 d of treatments.  
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Figure 1. PPARδ activation, inhibition, or siRNA knockdown affects TG loss in t10c12 
CLA treated adipocytes. A-C) Triglyceride (TG) levels were measured in 3T3-L1 
adipocytes after incubation with LA (-) or t10c12 CLA (+), with or without GW0742, 
GSK0660, or siRNA [control (CON) or specific for PPARδ (siPPARδ)] for 24 h. D) A 
representative western blot of the siRNA knockdown of PPARδ is shown. Each bar 
represents the mean + SEM, n=3, and is representative of three independent experiments 
for A-C, or represents three independent experiments for D. Means not sharing a 
common letter differ, P ≤  0.05. 
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Figure 2. PPARδ regulated genes and MCP1 have increased expression, and MCP1 
expression is affected by a PPARδ agonist or antagonist, in t10c12 CLA treated 
adipocytes. A-B) The mRNA from 3T3-L1 adipocytes treated with LA (-) or t10c12 CLA 
(+) for 12 h [with or without GW0742 (0742) or GSK0660 (0660)], and was then isolated 
and analyzed by real time PCR using primers for the following genes:  MCP1, 
ANGPTL4, CPT1a, and PDK4. Each bar represents the mean + SEM, n=3 independent 
experiments. Means not sharing a common letter differ, P ≤  0.05. 
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Figure 3. Rates of fatty acid biosynthesis, lipolysis, and oxidation are affected by t10c12 
CLA and GSK0660. A) Adipocytes were treated with LA (-) or t10c12 CLA (+), with or 
without GSK0660 (0660), for 24 h and then labeled with [14C]-acetate to determine the 
rate of fatty acid biosynthesis. B) As in A except that the amount of lipid released into the 
media at 12 h was measured. C) As in A except cells were labeled with [14C]-oleate at 12 
h after treatment and the amount of [14C]-CO2 released was measured. Each bar 
represents the mean + SEM, n=3, and is representative of three independent experiments. 
Means not sharing a common letter differ, P ≤  0.05. 
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Figure 4. T10c12 CLA, with or without a PPARδ agonist or antagonist, affects AMPK 
activity and AMPK’s interaction with PPARδ. A) 3T3-L1 adipocytes were treated with 
LA (-) or t10c12 CLA (+) for 12 h, with or without GW0742 (0742) or GSK0660 (0660). 
A representative immunoblot indicates the AMPK protein detected with antibody to 
phosphorylated AMPK (p-AMPK) or total AMPK (AMPK), respectively. The ratio of p-
AMPK to AMPK is indicated in the bar graph, and each bar corresponds to the treatment 
described below the immunoblots. B) Cell extracts from adipocytes treated with LA (-) or 
t10c12 CLA (+) for 12 h were immunoprecipitated with antibody to PPARδ (IP: PPARδ). 
Input (5% Input) or immunoprecipitated proteins were detected by immunoblot analysis 
using antibody to total AMPK or PPARδ (IB: AMPK or PPARδ). The ratios of AMPK to 
PPARδ for the immunoprecipitated samples are shown in the bar graph according to the 
CLA (-) or (+) designation. Each bar represents the mean + SEM, n=3 independent 
experiments.  Means not sharing a common letter differ, P ≤  0.05. 
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Figure 5. PPARγ and PPARδ bind to RXRα in t10c12 CLA treated adipocytes. 
Adipocytes were treated with LA (-) or t10c12 CLA (+), with or without GW0742 (0742) 
and extracts were immunoprecipitated using antibody to RXRα (IP: RXRα). 
Representative immunoblots demonstrate the amounts of protein detected in the input 
(5% Input) and immunoprecipitated samples for PPARγ, PPARδ, and RXRα. The ratios 
of PPARγ or PPARδ to RXRα are shown in the bar graph according to the treatment 
described below the immunoblots. Each bar represents the mean + SEM, n=3 
independent experiments.  Means not sharing a common letter differ, P ≤  0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
115
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI. Implications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
116
         Obesity has reached epidemic proportions in the United States and other developed 
countries, and is increasing even in the developing countries. T10c12 CLA causes fat loss 
in several mammalian models, particularly mice, and in human adipocytes. However, 
t10c12 CLA has not been demonstrated to be effective for TG loss in humans. 
Deciphering the mechanisms by which t10c12 CLA reduces fat in mammals might lead 
to therapies to prevent obesity. Currently, the mechanisms utilized by t10c12 CLA to 
cause fat loss are not known. The goal of this research was to discover some of the 
mechanisms utilized by t10c12 CLA to cause TG loss in adipocytes.  
          Here we demonstrated that the strong activation of AMPK induced by t10c12 CLA 
explained much of its isomer-specific delipidation effect in adipocytes. AMPK is an 
evolutionarily conserved protein kinase that regulates energy balance in cells. AMPK is a 
master regulator that  reduces anabolic biosynthesis and increase catabolic processes to 
increase cellular energy levels. The inhibited lipid synthesis and enhanced fatty acid 
oxidation triggered by activated AMPK helps explain the dramatic fat loss and variety of 
physiological and molecular responses observed in t10c12 CLA-treated 3T3-L1 
adipocytes and WAT in mice. The AMPK inhibitor Comp.C was able to attenuate 
changes in several key metabolic or regulatory proteins known to be inhibited by AMPK 
phosphorylation, including ACC, SREBP1c, PPARγ, C/EBPα, FAS, HMGR, ChREBP 
[Figure 1]. This results support our proposed role of AMPK as a master regulatory node 
in the response to t10c12 CLA. Our results showed AMPK was activated within 30 
minutes, which positioned AMPK upstream of the later ISR and inflammatory responses 
in t10c12 CLA treatments [Figure 1]. Comp.C treatment also  eliminated the ISR 
indictors ATF4 and ATF3 proteins and also reduced the amount of NF-κB translocated to 
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the nucleus, and inhibited MCP-1 mRNA levels. In conclusion, AMPK inhibitor comp.C 
inhibits all of the key indicators we tested in the response to t10c12 CLA.  
         We also demonstrated that activated AMPK could mimic many of the responses 
observed in t10c12 CLA treated adipocytes.  We demonstrated this in several ways. 
T10c12 CLA’s delipidation effects were enhanced by metformin in 3T3-L1 adipocytes 
and ML mice. More convincingly, phenformin, a stronger AMPK activator than 
metformin, caused TG losses similar to those caused by t10c12 CLA, and had a very 
similar transcriptome response as measured by microarray analysis. This provides strong 
support for the hypothesis that AMPK activation is sufficient to explain the majority of 
the responses to t10c12 CLA. The inability of phenformin to cause fat loss in humans is 
likely due to the uptake, distribution, and metabolism of the drug in the body. The 
combination of t10c12 CLA and metformin has therapeutic potential in humans and 
needs to be tested in human trials.  
          The inflammatory response was reported to be induced in t10c12 CLA-treated 
adipocytes. To answer the question whether an inflammatory response is required for 
effective delipidation by CLA, we explored which aspects of the inflammatory response 
were required. We found that the inhibition of NFkB attenuated TG loss in CLA treated 
adipocytes [Figure 1]. In support of the role of the inflammatory response, TNFα, a 
strong inflammatory cytokine, enhanced CLA’s ability to cause fat loss [see model in 
Figure 1]. Interestingly, we found TNFα activated AMPK and TNFα’s ability to 
delipidate was blocked by compound C. A comparison of AMPK activation, COX 
induction, and TG loss led to a model that suggested both AMPK and COX induction 
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were required for TG loss, and led us to more specifically investigate the role of 
prostaglandins in the CLA-meidated TG loss.   
          Our inhibitor studies indicated prostaglandins, Cox2, and PLA2 mediate at least 
part of the inflammatory response required for t10c12 CLA-mediated delipidation [Figure 
1]. Specifically, previous studies in the Miner laboratory found treating mice with a delta-
6 desaturase inhibitor (SC-26196) to reduce the production of arachidonic acid, the 
substrate for prostaglandin biosynthesis by Cox1/ 2, weakly inhibited t10c12 CLA-
induced delipidation . In our studies in 3T3-L1 adipocytes, we used an alternative 
inhibitor delta-5, 6-desaturase inhibitor (CP-24879) because SC-26196 was no longer 
available, and found it inhibited t10c12 CLA-mediated delipidation [Figure 1]. Both 
ibuprofen and indomethacin, non-selective Cox1/2 inhibitors with different chemical 
structures, also inhibited t10c12 CLA-mediated delipidation [Figure 1]. Increased 
phosphorylation of PLA2, which regulates PG biosynthesis by cleaving membrane lipids 
to generate arachidonic acid, in t10c12 CLA-treated adipocytes further indicates the 
important role of prostaglandins [Figure 1].  These inhibitor studies suggested 
prostaglandins were required for efficient TG loss. We next used prostaglandin “add-
back” treatments to better define their role.  
 Our hypothesis was that activated AMPK and prostaglandins were sufficient to 
cause TG loss. To test this, we used metformin to activate AMPK without creating a 
strong inflammatory response. We then added individual prostaglandins or arachidonic 
acid to test our hypothesis. Metformin alone causes a modest delipidation because it 
moderately activated AMPK. Individual prostaglandins had little effect when added alone. 
However, we found PGH2 (precursor to the PG family), or PGF2α caused strong 
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delipidation when used in combination with metformin. This supports the idea that a 
major component of the inflammatory response responsible for TG loss in 3T3-L1 
adipocytes are the prostaglandins. However, the prostaglandins are probably less 
important in the animal as COX2 mRNA levels are low and not strongly induced, Most 
likely some other aspect of the inflammatory response plays an equivalent role in WAT 
in animals.  One possible mechanism utilized by PGF2α’s for its delipidation effects is 
that it results in phosphorylation of PPARγ [31] or inhibition of PPARγ expression [32]. 
Our data indicates an alternative to a stronger activator of AMPK in adipocytes might be 
to use an AMPK activator and a second compound that leads to higher prostanoid levels.  
         Phenformin causes an inflammatory response and TG loss, while little inflammation 
and TG loss are observed with metformin. This supports the premise that inflammation is 
needed for TG loss. The microarray analysis of 3T3-L1 adipocytes treated with t10c12 
CLA or phenformin demonstrated similar changes in transcript profiles, suggesting the 
similar abilities of t10c12 CLA and phenformin to strongly activate AMPK and to cause 
similar reductions in TG levels were due to activation of similar pathways. These results 
suggest strong AMPK activation in adipocytes is sufficient for a robust delipidation 
response. This implies t10c12 CLA only needs to activate AMPK in adipocytes to 
account for the majority of its effects. However, phenformin appears to act at muscles in 
humans as it was reported to cause toxic lactic acidosis, which limited its application in 
humans, and explains why it does not cause significant fat loss in animals.  
          Our further studies showed t10c12 CLA is selective in the cellular response. We 
found that t10c12 CLA strongly induced an ISR in 3T3-L1 adipocytes, but fibroblasts did 
not show this response. Our microarray analysis of liver tissues of mice treated with 
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t10c12 CLA showed a weak ISR, and lacked a significant delipidation or inflammatory 
response. Most drugs or nutritional supplements do not show strong tissue specificity and 
generate undesirable side effects in non-target tissues. This provides t10c12 CLA  
potential advantage as an adipocyte specific chemical for obesity therapeutics. To extend 
our knowledge of CLA’s cell-type selectivity, a microarray study of other types of tissues 
in mice responding to t10c12 CLA is worth performing in the future. If the t10c12 CLA 
response is preferentially selective for adipocytes, it provides an excellent platform for 
adding additional less-selective nutritional molecules for reducing adiposity that 
collectively provide a more adipocyte specific effect, and improve CLA’s advantage in 
clinical trials. 
         Our studies demonstrated cross regulation of AMPK and SIRT1 was occurring in 
t10c12 CLA treatment [Figure 1]. Activated AMPK affected the amount of SIRT1-
related deacetylation of NF-κB in the molecular response to t10c12 CLA, possibly via 
changes in the fatty acid oxidation dependent NAD+/NADH ratio [151]. SIRT1 affected 
the amount of activated AMPK, as SIRT1 inhibitors attenuated AMPK activation at 12 h. 
SIRT1 inhibitors did not affect AMPK activation in the first 2 h of t10c12 CLA treatment, 
indicating early AMPK activation did not depend on SIRT1 activity. The combined data 
support the hypothesis that both AMPK and SIRT1 positively regulate each other in the 
response to t10c12 CLA-treated adipocytes. To our surprise, SIRT1 utilized mechanisms 
that both promoted and inhibited the inflammatory response in t10c12 CLA treatments. 
Our study showed that SIRT1 had a pro-inflammatory bias in the response to t10c12 
CLA. It could be mediated through facilitating activation of AMPK as phenformin, a 
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strong AMPK activator, can cause an inflammatory and TG reduction response in 
adipocytes. The understanding on the detailed mechanism is still unclear.  
          Our chemical studies suggested that both AMPK activation and reduced PPARγ 
activity are important for reducing TG levels in the response to t10c12 CLA [Figure 1]. 
The key outcome is determined by whether AMPK and PPARγ becomes activated and 
inhibits the activity of the other. In opposition to AMPK activity, PPARγ is required for 
differentiation and maintenance of the adipocytes. Activation of PPARγ by 
thiazolidinediones (TZDs) strongly attenuates t10c12 CLA effects in adipocytes. PPARγ 
is also antagonistic NF-κB in t10c12 CLA-treated adipocytes and is considered anti-
inflammatory. In contrast, PPARγ antagonist GW9662 and t10c12 CLA are synergistic 
for delipidation. This suggests an approach combining t10c12 CLA with nutritional 
supplements that further inhibit PPARγ in adipocytes is promising for reducing adiposity.   
          PPARδ plays a positive role in reducing TG content in t10c12 CLA treated 
adipocytes [Figure 1]. PPARδ facilitates TG loss in CLA treated adipocytes by increasing 
fatty acid oxidation. PPARδ had increased binding to AMPK in CLA treated adipocytes, 
subsequently affected AMPK activity. PPARδ reduces PPARγ activity by a second 
mechanism that appears to depend on the reduced amounts and activity of PPARγ caused 
by AMPK. This second mechanism appears to affect the competition for RXR, the 
required heterodimeric partner for PPARγ, PPARδ, LXR and RAR [175, 176, 178]. This 
suggested the low levels of PPARγ activity, caused by the presence of t10c12 CLA, can 
be further decreased by competition for RXR by other ligand-activated nuclear receptors.  
In conclusion, activated AMPK [112] and, activated PPARδ, inhibit PPARγ activity. This 
provides a promising platform for combinations of t10c12 CLA with less tissue-specific 
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drugs such as metformin [111] or PPARδ agonists to attain more effective reduction of 
adiposity. 
          Currently, CLA is used in much lower dosage in human studies than in animal 
studies [22-23]. Some side effects of CLA were reported in the presence of extreme 
reduction of fat content in fat tissues when CLA was used at high dosage, including 
lipodystrophy, insulin resistance, elevated oxidative stress, hyperinsulinemia and liver 
steatosis in mice. For enhancing the delipidation of CLA in human trials, it is preferable 
to have a lower dose of CLA. Our goal is to accomplish this by looking for mechanism-
based synergistic effects of drugs or nutritional supplements. Therefore, the modest fat 
loss in the fat tissues would be attained at a lower dosage of CLA. Our studies discovered 
several mechanisms which play important roles in CLA effects and provide good targets 
for synergy. This provides us an excellent platform to figure out the important factors 
involved in CLA effects, and subsequently test if their agonists or antagonists are able to 
enhance CLA delipidation when CLA is used at the low dosage in human trials. Our 
studies also help figure out how these side effects occur in CLA treatment. This also 
helps reveal the nutritionally regulated sensors and regulatory networks that can be 
utilized to reduce adiposity.  
One of the most novel aspects of our findings are that PPARγ and PPARδ appear 
to regulate AMPK activity. This finding contrasts with the vast majority of current 
publications that consider PPARγ and PPARδ to act as transcription factors, capable of 
both activation or repression. Very little has been published on the non-genomic effects 
of these two proteins. Our results demonstrate PPARγ and PPARδ can affect AMPK 
activity levels without apparent changes in transcription of this gene, as AMPK protein 
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levels do not change. Our demonstration that CLA affects the PPARγ/SIRT1 interaction 
and the PPARδ/AMPK interaction, together with the known ability of SIRT1 to interact 
LKB1, an upstream kinase of AMPK, provides a remarkably intimate view of this cast of 
metabolic regulators and their ability to cross regulate each other’s behavior.  
         The question of how t10c12 CLA causes these changes in the SIRT1/AMPK/ 
PPARδ/ PPARγ axis remains unknown. AMPK is affected by a large diversity of stimuli, 
as is appropriate for its central role in cell energy homeostasis. This diversity of potential 
stimuli precludes a simple exploration of how AMPK is activated by t10c12 CLA. The 
whole area of how fatty acids signal to key regulatory proteins such as AMPK is poorly 
understood and this lack of knowledge makes deciphering the mechanisms used by 
t10c12 CLA more difficult. T10c12 CLA is known to preferentially accumulate in 
adipocytes in animals and humans. Our results indicate adipocytes are particularly 
sensitive to its effects for unknown reasons. The combination of preferential 
accumulation and increased sensitivity are ideal for a tissue specific effect. The challenge 
is to find other drugs or nutritional molecules that have similar profiles and are capable of 
causing synergistic effects in the key SIRT1/AMPK/ PPARδ/ PPARγ axis.  
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Figure 1. Working model for t10c12 CLA signaling. CLA or phenformin strongly 
activates AMPK to a phosphorylated state (p-AMPK), which initiates an integrated stress 
response (ISR): either step might be cell-type specific for t10c12 CLA. The ISR activates 
the NF-κB, JNK, and ERK axis, which together initiate the inflammatory response and 
delipidation. Metformin with TNFα produces a similar delipidation. AMPK, NF-κB, JNK, 
or ERK directly inhibit PPARγ, which normally inhibits inflammation. RAR, LXR or 
PPARβ/δ compete with PPARγ for RXR. Either activated AMPK or SIRT1 affects the 
other. Phospholipase A2 (PLA2) is activated by phosphorylation (p-PLA2) by either JNK 
or ERK, increasing the amounts of arachidonic acid (AA), the substrate for cyclo-
oxygenase 1 or 2 (Cox1/2), for increased prostaglandins (PG), which are inhibitory to 
lipogenesis. The fatty acid precursors to AA are indicated as LA, γ-LA, and DGLA. 
Inhibitors we have been found to reduce the effects of t10c12 CLA are italicized.  
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